

Bill no.:	<u>Committee Print 4</u>
Amendment no.:	_____
Date offered:	<u>6/19/02</u>
Disposition:	<u>Agreed to, as amended, by 30 yeas and 23 nays</u>

[COMMITTEE PRINT]

**TITLE I—MEDICARE
PRESCRIPTION DRUG BENEFIT**

SEC. 101. ESTABLISHMENT OF A MEDICARE PRESCRIPTION DRUG BENEFIT.

(a) IN GENERAL.—Title XVIII is amended—

(1) by redesignating part D as part E; and

(2) by inserting after part C the following new part:

“PART D—VOLUNTARY PRESCRIPTION DRUG BENEFIT
PROGRAM

**“SEC. 1860A. BENEFITS; ELIGIBILITY; ENROLLMENT;
AND COVERAGE PERIOD.**

“(a) PROVISION OF QUALIFIED PRESCRIPTION DRUG COVERAGE THROUGH ENROLLMENT IN PLANS.—Subject to the succeeding provisions of this part, each individual who is entitled to benefits under part A or is enrolled under part B is entitled to obtain qualified prescription drug coverage (described in section 1860B(a)) as follows:

“(1) MEDICARE+CHOICE PLAN.—If the individual is eligible to enroll in a Medicare+Choice plan that provides qualified prescription drug coverage under section 1851(j), the individual may enroll in the plan and obtain coverage through such plan.

“(2) PRESCRIPTION DRUG PLAN.—If the individual is not enrolled in a Medicare+Choice plan that provides qualified prescription drug coverage, the individual may enroll under this part in a prescription drug plan (as defined in section 1860J(a)(5)).

Such individuals shall have a choice of such plans under section 1860E(d).

“(b) GENERAL ELECTION PROCEDURES.—

“(1) IN GENERAL.—An individual eligible to make an election under subsection (a) may elect to enroll in a prescription drug plan under this part, or elect the option of qualified prescription drug coverage under a Medicare+Choice plan under part C, and to change such



1 election only in such manner and form as may be pre-
2 scribed by regulations of the Administrator of the Medicare
3 Benefits Administration (appointed under section 1808(b))
4 (in this part referred to as the 'Medicare Benefits Adminis-
5 trator') and only during an election period prescribed in or
6 under this subsection.

7 "(2) ELECTION PERIODS.—

8 "(A) IN GENERAL.—Except as provided in this
9 paragraph, the election periods under this subsection
10 shall be the same as the coverage election periods
11 under the Medicare+Choice program under section
12 1851(e), including—

13 "(i) annual coordinated election periods; and

14 "(ii) special election periods.

15 In applying the last sentence of section 1851(e)(4) (re-
16 lating to discontinuance of a Medicare+Choice election
17 during the first year of eligibility) under this subpara-
18 graph, in the case of an election described in such sec-
19 tion in which the individual had elected or is provided
20 qualified prescription drug coverage at the time of such
21 first enrollment, the individual shall be permitted to en-
22 roll in a prescription drug plan under this part at the
23 time of the election of coverage under the original fee-
24 for-service plan.

25 "(B) INITIAL ELECTION PERIODS.—

26 "(i) INDIVIDUALS CURRENTLY COVERED.—In
27 the case of an individual who is entitled to benefits
28 under part A or enrolled under part B as of No-
29 vember 1, 2004, there shall be an initial election
30 period of 6 months beginning on that date.

31 "(ii) INDIVIDUAL COVERED IN FUTURE.—In
32 the case of an individual who is first entitled to
33 benefits under part A or enrolled under part B
34 after such date, there shall be an initial election pe-
35 riod which is the same as the initial enrollment pe-
36 riod under section 1837(d).



1 “(C) ADDITIONAL SPECIAL ELECTION PERIODS.—
2 The Administrator shall establish special election
3 periods—

4 “(i) in cases of individuals who have and invol-
5 untarily lose prescription drug coverage described
6 in subsection (c)(2)(C);

7 “(ii) in cases described in section 1837(h) (re-
8 lating to errors in enrollment), in the same manner
9 as such section applies to part B;

10 “(iii) in the case of an individual who meets
11 such exceptional conditions (including conditions
12 provided under section 1851(e)(4)(D)) as the Ad-
13 ministrator may provide; and

14 “(iv) in cases of individuals (as determined by
15 the Administrator) who become eligible for pre-
16 scription drug assistance under title XIX under
17 section 1935(d).

18 “(c) GUARANTEED ISSUE; COMMUNITY RATING; AND
19 NONDISCRIMINATION.—

20 “(1) GUARANTEED ISSUE.—

21 “(A) IN GENERAL.—An eligible individual who is
22 eligible to elect qualified prescription drug coverage
23 under a prescription drug plan or Medicare+Choice
24 plan at a time during which elections are accepted
25 under this part with respect to the plan shall not be
26 denied enrollment based on any health status-related
27 factor (described in section 2702(a)(1) of the Public
28 Health Service Act) or any other factor.

29 “(B) MEDICARE+CHOICE LIMITATIONS PER-
30 MITTEL.—The provisions of paragraphs (2) and (3)
31 (other than subparagraph (C)(i), relating to default en-
32 rollment) of section 1851(g) (relating to priority and
33 limitation on termination of election) shall apply to
34 PDP sponsors under this subsection.

35 “(2) COMMUNITY-RATED PREMIUM.—

36 “(A) IN GENERAL.—In the case of an individual
37 who maintains (as determined under subparagraph (C))

1 continuous prescription drug coverage since the date
2 the individual first qualifies to elect prescription drug
3 coverage under this part, a PDP sponsor or
4 Medicare+Choice organization offering a prescription
5 drug plan or Medicare+Choice plan that provides
6 qualified prescription drug coverage and in which the
7 individual is enrolled may not deny, limit, or condition
8 the coverage or provision of covered prescription drug
9 benefits or increase the premium under the plan based
10 on any health status-related factor described in section
11 2702(a)(1) of the Public Health Service Act or any
12 other factor.

13 “(B) LATE ENROLLMENT PENALTY.—In the case
14 of an individual who does not maintain such continuous
15 prescription drug coverage (as described in subpara-
16 graph (C)), a PDP sponsor or Medicare+Choice orga-
17 nization may (notwithstanding any provision in this
18 title) adjust the premium otherwise applicable or im-
19 pose a pre-existing condition exclusion with respect to
20 qualified prescription drug coverage in a manner that
21 reflects additional actuarial risk involved. Such a risk
22 shall be established through an appropriate actuarial
23 opinion of the type described in subparagraphs (A)
24 through (C) of section 2103(c)(4).

25 “(C) CONTINUOUS PRESCRIPTION DRUG COV-
26 ERAGE.—An individual is considered for purposes of
27 this part to be maintaining continuous prescription
28 drug coverage on and after the date the individual first
29 qualifies to elect prescription drug coverage under this
30 part if the individual establishes that as of such date
31 the individual is covered under any of the following pre-
32 scription drug coverage and before the date that is the
33 last day of the 63-day period that begins on the date
34 of termination of the particular prescription drug cov-
35 erage involved (regardless of whether the individual
36 subsequently obtains any of the following prescription
37 drug coverage):

1 “(i) COVERAGE UNDER PRESCRIPTION DRUG
2 PLAN OR MEDICARE+CHOICE PLAN.—Qualified
3 prescription drug coverage under a prescription
4 drug plan or under a Medicare+Choice plan.

5 “(ii) MEDICAID PRESCRIPTION DRUG COV-
6 ERAGE.—Prescription drug coverage under a med-
7 icaid plan under title XIX, including through the
8 Program of All-inclusive Care for the Elderly
9 (PACE) under section 1934, through a social
10 health maintenance organization (referred to in
11 section 4104(c) of the Balanced Budget Act of
12 1997), or through a Medicare+Choice project that
13 demonstrates the application of capitation payment
14 rates for frail elderly medicare beneficiaries
15 through the use of a interdisciplinary team and
16 through the provision of primary care services to
17 such beneficiaries by means of such a team at the
18 nursing facility involved.

19 “(iii) PRESCRIPTION DRUG COVERAGE UNDER
20 GROUP HEALTH PLAN.—Any outpatient prescrip-
21 tion drug coverage under a group health plan, in-
22 cluding a health benefits plan under the Federal
23 Employees Health Benefit Plan under chapter 89
24 of title 5, United States Code, and a qualified re-
25 tiree prescription drug plan as defined in section
26 1860H(f)(1), but only if (subject to subparagraph
27 (E)(ii)) the coverage provides benefits at least
28 equivalent to the benefits under a qualified pre-
29 scription drug plan.

30 “(iv) PRESCRIPTION DRUG COVERAGE UNDER
31 CERTAIN MEDIGAP POLICIES.—Coverage under a
32 medicare supplemental policy under section 1882
33 that provides benefits for prescription drugs
34 (whether or not such coverage conforms to the
35 standards for packages of benefits under section
36 1882(p)(1)), but only if the policy was in effect on
37 January 1, 2005, and if (subject to subparagraph

(E)(ii)) the coverage provides benefits at least equivalent to the benefits under a qualified prescription drug plan.

“(v) STATE PHARMACEUTICAL ASSISTANCE PROGRAM.—Coverage of prescription drugs under a State pharmaceutical assistance program, but only if (subject to subparagraph (E)(ii)) the coverage provides benefits at least equivalent to the benefits under a qualified prescription drug plan.

“(vi) VETERANS’ COVERAGE OF PRESCRIPTION DRUGS.—Coverage of prescription drugs for veterans under chapter 17 of title 38, United States Code, but only if (subject to subparagraph (E)(ii)) the coverage provides benefits at least equivalent to the benefits under a qualified prescription drug plan.

“(D) CERTIFICATION.—For purposes of carrying out this paragraph, the certifications of the type described in sections 2701(e) of the Public Health Service Act and in section 9801(e) of the Internal Revenue Code shall also include a statement for the period of coverage of whether the individual involved had prescription drug coverage described in subparagraph (C).

“(E) DISCLOSURE.—

“(i) IN GENERAL.—Each entity that offers coverage of the type described in clause (iii), (iv), (v), or (vi) of subparagraph (C) shall provide for disclosure, consistent with standards established by the Administrator, of whether such coverage provides benefits at least equivalent to the benefits under a qualified prescription drug plan.

“(ii) WAIVER OF LIMITATIONS.—An individual may apply to the Administrator to waive the requirement that coverage of such type provide benefits at least equivalent to the benefits under a qualified prescription drug plan, if the individual establishes that the individual was not adequately

1 informed that such coverage did not provide such
2 level of benefits.

3 "(F) CONSTRUCTION.—Nothing in this section
4 shall be construed as preventing the disenrollment of
5 an individual from a prescription drug plan or a
6 Medicare+Choice plan based on the termination of an
7 election described in section 1851(g)(3), including for
8 non-payment of premiums or for other reasons speci-
9 fied in subsection (d)(3), which takes into account a
10 grace period described in section 1851(g)(3)(B)(i).

11 "(3) NONDISCRIMINATION.—A PDP sponsor offering
12 a prescription drug plan shall not establish a service area
13 in a manner that would discriminate based on health or
14 economic status of potential enrollees.

15 "(d) EFFECTIVE DATE OF ELECTIONS.—

16 "(1) IN GENERAL.—Except as provided in this section,
17 the Administrator shall provide that elections under sub-
18 section (b) take effect at the same time as the Adminis-
19 trator provides that similar elections under section 1851(e)
20 take effect under section 1851(f).

21 "(2) NO ELECTION EFFECTIVE BEFORE 2005.—In no
22 case shall any election take effect before January 1, 2005.

23 "(3) TERMINATION.—The Administrator shall provide
24 for the termination of an election in the case of—

25 "(A) termination of coverage under both part A
26 and part B; and

27 "(B) termination of elections described in section
28 1851(g)(3) (including failure to pay required pre-
29 miums).

30 **"SEC. 1860B. REQUIREMENTS FOR QUALIFIED PRE-**
31 **SCRIPTION DRUG COVERAGE.**

32 "(a) REQUIREMENTS.—

33 "(1) IN GENERAL.—For purposes of this part and
34 part C, the term 'qualified prescription drug coverage'
35 means either of the following:

36 "(A) STANDARD COVERAGE WITH ACCESS TO NE-
37 GOTIATED PRICES.—Standard coverage (as defined in



1 subsection (b)) and access to negotiated prices under
2 subsection (d).

3 "(B) ACTUARIALLY EQUIVALENT COVERAGE WITH
4 ACCESS TO NEGOTIATED PRICES.—Coverage of covered
5 outpatient drugs which meets the alternative coverage
6 requirements of subsection (c) and access to negotiated
7 prices under subsection (d), but only if it is approved
8 by the Administrator, as provided under subsection (c).

9 "(2) PERMITTING ADDITIONAL OUTPATIENT PRE-
10SCRIPTION DRUG COVERAGE.—

11 "(A) IN GENERAL.—Subject to subparagraph (B),
12 nothing in this part shall be construed as preventing
13 qualified prescription drug coverage from including cov-
14 erage of covered outpatient drugs that exceeds the cov-
15 erage required under paragraph (1), but any such addi-
16 tional coverage shall be limited to coverage of covered
17 outpatient drugs.

18 "(B) DISAPPROVAL AUTHORITY.—The Adminis-
19 trator shall review the offering of qualified prescription
20 drug coverage under this part or part C. If the Admin-
21 istrator finds that, in the case of a qualified prescrip-
22 tion drug coverage under a prescription drug plan or
23 a Medicare+Choice plan, that the organization or spon-
24 sor offering the coverage is engaged in activities in-
25 tended to discourage enrollment of classes of eligible
26 medicare beneficiaries obtaining coverage through the
27 plan on the basis of their higher likelihood of utilizing
28 prescription drug coverage, the Administrator may ter-
29 minate the contract with the sponsor or organization
30 under this part or part C.

31 "(3) APPLICATION OF SECONDARY PAYOR PROVI-
32 SIONS.—The provisions of section 1852(a)(4) shall apply
33 under this part in the same manner as they apply under
34 part C.

35 "(b) STANDARD COVERAGE.—For purposes of this part,
36 the 'standard coverage' is coverage of covered outpatient drugs



1 (as defined in subsection (f)) that meets the following require-
2 ments:

3 "(1) DEDUCTIBLE.—The coverage has an annual
4 deductible—

5 "(A) for 2005, that is equal to \$250; or

6 "(B) for a subsequent year, that is equal to the
7 amount specified under this paragraph for the previous
8 year increased by the percentage specified in paragraph
9 (5) for the year involved.

10 Any amount determined under subparagraph (B) that is
11 not a multiple of \$10 shall be rounded to the nearest mul-
12 tiple of \$10.

13 "(2) LIMITS ON COST-SHARING.—

14 "(A) IN GENERAL.—The coverage has cost-sharing
15 (for costs above the annual deductible specified in para-
16 graph (1) and up to the initial coverage limit under
17 paragraph (3)) as follows:

18 "(i) FIRST COPAYMENT RANGE.—For costs
19 above the annual deductible specified in paragraph
20 (1) and up to amount specified in subparagraph
21 (C), the cost-sharing—

22 "(I) is equal to 20 percent; or

23 "(II) is actuarially equivalent (using proc-
24 esses established under subsection (e)) to an
25 average expected payment of 20 percent of
26 such costs.

27 "(ii) SECONDARY COPAYMENT RANGE.—For
28 costs above the amount specified in subparagraph
29 (C) and up to the initial coverage limit, the cost-
30 sharing—

31 "(I) is equal to 50 percent; or

32 "(II) is actuarially consistent (using proc-
33 esses established under subsection (e)) with an
34 average expected payment of 50 percent of
35 such costs.

36 "(B) USE OF TIERED COPAYMENTS.—Nothing in
37 this part shall be construed as preventing a PDP sponsor

1 sor from applying tiered copayments, so long as such
2 tiered copayments are consistent with subparagraph
3 (A).

4 “(C) INITIAL COPAYMENT THRESHOLD.—The
5 amount specified in this subparagraph—

6 “(i) for 2005, is equal to \$1,000; or

7 “(ii) for a subsequent year, is equal to the
8 amount specified in this subparagraph for the pre-
9 vious year, increased by the annual percentage in-
10 crease described in paragraph (5) for the year in-
11 volved.

12 Any amount determined under clause (ii) that is not a
13 multiple of \$10 shall be rounded to the nearest mul-
14 tiple of \$10.

15 “(3) INITIAL COVERAGE LIMIT.—Subject to paragraph
16 (4), the coverage has an initial coverage limit on the max-
17 imum costs that may be recognized for payment purposes
18 (above the annual deductible)—

19 “(A) for 2005, that is equal to \$2,000; or

20 “(B) for a subsequent year, that is equal to the
21 amount specified in this paragraph for the previous
22 year, increased by the annual percentage increase de-
23 scribed in paragraph (5) for the year involved.

24 Any amount determined under subparagraph (B) that is
25 not a multiple of \$25 shall be rounded to the nearest mul-
26 tiple of \$25.

27 “(4) CATASTROPHIC PROTECTION.—

28 “(A) IN GENERAL.—Notwithstanding paragraph
29 (3), the coverage provides benefits with no cost-sharing
30 after the individual has incurred costs (as described in
31 subparagraph (C)) for covered outpatient drugs in a
32 year equal to the annual out-of-pocket threshold speci-
33 fied in subparagraph (B).

34 “(B) ANNUAL OUT-OF-POCKET THRESHOLD.—For
35 purposes of this part, the annual out-of-pocket thresh-
36 old specified in this subparagraph—

37 “(i) for 2005, is equal to \$4,500; or



1 “(ii) for a subsequent year, is equal to the
2 amount specified in this subparagraph for the pre-
3 vious year, increased by the annual percentage in-
4 crease described in paragraph (5) for the year in-
5 volved.

6 Any amount determined under clause (ii) that is not a
7 multiple of \$100 shall be rounded to the nearest mul-
8 tiple of \$100.

9 “(C) APPLICATION.—In applying subparagraph
10 (A)—

11 “(i) incurred costs shall only include costs in-
12 curred for the annual deductible (described in para-
13 graph (1)), cost-sharing (described in paragraph
14 (2)), and amounts for which benefits are not pro-
15 vided because of the application of the initial cov-
16 erage limit described in paragraph (3); and

17 “(ii) such costs shall be treated as incurred
18 only if they are paid by the individual, under sec-
19 tion 1860G, or under title XIX and the individual
20 is not reimbursed (through insurance or otherwise)
21 by another person for such costs.

22 “(5) ANNUAL PERCENTAGE INCREASE.—For purposes
23 of this part, the annual percentage increase specified in
24 this paragraph for a year is equal to the annual percentage
25 increase in average per capita aggregate expenditures for
26 covered outpatient drugs in the United States for medicare
27 beneficiaries, as determined by the Administrator for the
28 12-month period ending in July of the previous year.

29 “(c) ALTERNATIVE COVERAGE REQUIREMENTS.—A pre-
30 scription drug plan or Medicare+Choice plan may provide a
31 different prescription drug benefit design from the standard
32 coverage described in subsection (b) so long as the following re-
33 quirements are met and the plan applies for, and receives, the
34 approval of the Administrator for such benefit design:

35 “(1) ASSURING AT LEAST ACTUARIALLY EQUIVALENT
36 COVERAGE.—



1 “(A) ASSURING EQUIVALENT VALUE OF TOTAL
2 COVERAGE.—The actuarial value of the total coverage
3 (as determined under subsection (e)) is at least equal
4 to the actuarial value (as so determined) of standard
5 coverage.

6 “(B) ASSURING EQUIVALENT UNSUBSIDIZED
7 VALUE OF COVERAGE.—The unsubsidized value of the
8 coverage is at least equal to the unsubsidized value of
9 standard coverage. For purposes of this subparagraph,
10 the unsubsidized value of coverage is the amount by
11 which the actuarial value of the coverage (as deter-
12 mined under subsection (e)) exceeds the actuarial value
13 of the subsidy payments under section 1860H with re-
14 spect to such coverage.

15 “(C) ASSURING STANDARD PAYMENT FOR COSTS
16 AT INITIAL COVERAGE LIMIT.—The coverage is de-
17 signed, based upon an actuarially representative pat-
18 tern of utilization (as determined under subsection (e)),
19 to provide for the payment, with respect to costs in-
20 curred that are equal to the initial coverage limit under
21 subsection (b)(3), of an amount equal to at least the
22 sum of the following products:

23 “(i) FIRST COPAYMENT RANGE.—The product
24 of—

25 “(I) the amount by which the initial co-
26 payment threshold described in subsection
27 (b)(2)(C) exceeds the deductible described in
28 subsection (b)(1); and

29 “(II) 100 percent minus the cost-sharing
30 percentage specified in subsection
31 (b)(2)(A)(i)(I).

32 “(ii) SECONDARY COPAYMENT RANGE.—The
33 product of—

34 “(I) the amount by which the initial cov-
35 erage limit described in subsection (b)(3) ex-
36 ceeds the initial copayment threshold described
37 in subsection (b)(2)(C); and

1 “(II) 100 percent minus the cost-sharing
2 percentage specified in subsection
3 (b)(2)(A)(ii)(I).

4 “(2) CATASTROPHIC PROTECTION.—The coverage pro-
5 vides for beneficiaries the catastrophic protection described
6 in subsection (b)(4).

7 “(d) ACCESS TO NEGOTIATED PRICES.—

8 “(1) IN GENERAL.—Under qualified prescription drug
9 coverage offered by a PDP sponsor or a Medicare+Choice
10 organization, the sponsor or organization shall provide
11 beneficiaries with access to negotiated prices (including ap-
12 plicable discounts) used for payment for covered outpatient
13 drugs, regardless of the fact that no benefits may be pay-
14 able under the coverage with respect to such drugs because
15 of the application of cost-sharing or an initial coverage
16 limit (described in subsection (b)(3)). Insofar as a State
17 elects to provide medical assistance under title XIX for a
18 drug based on the prices negotiated by a prescription drug
19 plan under this part, the requirements of section 1927 shall
20 not apply to such drugs.

21 “(2) DISCLOSURE.—The PDP sponsor or
22 Medicare+Choice organization shall disclose to the Admin-
23 istrator (in a manner specified by the Administrator) the
24 extent to which discounts or rebates made available to the
25 sponsor or organization by a manufacturer are passed
26 through to enrollees through pharmacies and other dis-
27 pensers or otherwise. The provisions of section
28 1927(b)(3)(D) shall apply to information disclosed to the
29 Administrator under this paragraph in the same manner as
30 such provisions apply to information disclosed under such
31 section.

32 “(e) ACTUARIAL VALUATION; DETERMINATION OF AN-
33 NUAL PERCENTAGE INCREASES.—

34 “(1) PROCESSES.—For purposes of this section, the
35 Administrator shall establish processes and methods—

36 “(A) for determining the actuarial valuation of
37 prescription drug coverage, including—

1 “(i) an actuarial valuation of standard cov-
2 erage and of the reinsurance subsidy payments
3 under section 1860H;

4 “(ii) the use of generally accepted actuarial
5 principles and methodologies; and

6 “(iii) applying the same methodology for de-
7 terminations of alternative coverage under sub-
8 section (c) as is used with respect to determina-
9 tions of standard coverage under subsection (b);
10 and

11 “(B) for determining annual percentage increases
12 described in subsection (b)(5).

13 “(2) USE OF OUTSIDE ACTUARIES.—Under the proc-
14 esses under paragraph (1)(A), PDP sponsors and
15 Medicare+Choice organizations may use actuarial opinions
16 certified by independent, qualified actuaries to establish ac-
17 tuarial values.

18 “(f) COVERED OUTPATIENT DRUGS DEFINED.—

19 “(1) IN GENERAL.—Except as provided in this sub-
20 section, for purposes of this part, the term ‘covered out-
21 patient drug’ means—

22 “(A) a drug that may be dispensed only upon a
23 prescription and that is described in subparagraph
24 (A)(i) or (A)(ii) of section 1927(k)(2); or

25 “(B) a biological product described in clauses (i)
26 through (iii) of subparagraph (B) of such section or in-
27 sulin described in subparagraph (C) of such section,
28 and such term includes a vaccine licensed under section
29 351 of the Public Health Service Act and any use of a cov-
30 ered outpatient drug for a medically accepted indication (as
31 defined in section 1927(k)(6)).

32 “(2) EXCLUSIONS.—

33 “(A) IN GENERAL.—Such term does not include
34 drugs or classes of drugs, or their medical uses, which
35 may be excluded from coverage or otherwise restricted
36 under section 1927(d)(2), other than subparagraph (E)



1 thereof (relating to smoking cessation agents), or under
2 section 1927(d)(3).

3 “(B) AVOIDANCE OF DUPLICATE COVERAGE.—A
4 drug prescribed for an individual that would otherwise
5 be a covered outpatient drug under this part shall not
6 be so considered if payment for such drug is available
7 under part A or B for an individual entitled to benefits
8 under part A and enrolled under part B.

9 “(3) APPLICATION OF FORMULARY RESTRICTIONS.—A
10 drug prescribed for an individual that would otherwise be
11 a covered outpatient drug under this part shall not be so
12 considered under a plan if the plan excludes the drug under
13 a formulary and such exclusion is not successfully appealed
14 under section 1860C(f)(2).

15 “(4) APPLICATION OF GENERAL EXCLUSION PROVI-
16 SIONS.—A prescription drug plan or Medicare+Choice plan
17 may exclude from qualified prescription drug coverage any
18 covered outpatient drug—

19 “(A) for which payment would not be made if sec-
20 tion 1862(a) applied to part D; or

21 “(B) which are not prescribed in accordance with
22 the plan or this part.

23 Such exclusions are determinations subject to reconsider-
24 ation and appeal pursuant to section 1860C(f).

25 **“SEC. 1860C. BENEFICIARY PROTECTIONS FOR QUALI-**
26 **FIED PRESCRIPTION DRUG COVERAGE.**

27 “(a) GUARANTEED ISSUE. COMMUNITY-RELATED PRE-
28 MIUMS. ACCESS TO NEGOTIATED PRICES, AND NON-
29 DISCRIMINATION.—For provisions requiring guaranteed issue,
30 community-rated premiums, access to negotiated prices, and
31 nondiscrimination, see sections 1860A(c)(1), 1860A(c)(2),
32 1860B(d), and 1860F(b), respectively.

33 “(b) DISSEMINATION OF INFORMATION —

34 “(1) GENERAL INFORMATION.—A PDP sponsor shall
35 disclose, in a clear, accurate, and standardized form to
36 each enrollee with a prescription drug plan offered by the
37 sponsor under this part at the time of enrollment and at



1 least annually thereafter, the information described in sec-
2 tion 1852(c)(1) relating to such plan. Such information in-
3 cludes the following:

4 “(A) Access to covered outpatient drugs, including
5 access through pharmacy networks.

6 “(B) How any formulary used by the sponsor
7 functions.

8 “(C) Co-payments and deductible requirements,
9 including the identification of the tiered or other co-
10 payment level applicable to each drug (or class of
11 drugs).

12 “(D) Grievance and appeals procedures.

13 “(2) DISCLOSURE UPON REQUEST OF GENERAL COV-
14 ERAGE, UTILIZATION, AND GRIEVANCE INFORMATION.—
15 Upon request of an individual eligible to enroll under a pre-
16 scription drug plan, the PDP sponsor shall provide the in-
17 formation described in section 1852(c)(2) (other than sub-
18 paragraph (D)) to such individual.

19 “(3) RESPONSE TO BENEFICIARY QUESTIONS.—Each
20 PDP sponsor offering a prescription drug plan shall have
21 a mechanism for providing specific information to enrollees
22 upon request. The sponsor shall make available on a timely
23 basis, through an Internet website and in writing upon re-
24 quest, information on specific changes in its formulary.

25 “(4) CLAIMS INFORMATION.—Each PDP sponsor of-
26 fering a prescription drug plan must furnish to enrolled in-
27 dividuals in a form easily understandable to such individ-
28 uals an explanation of benefits (in accordance with section
29 1806(a) or in a comparable manner) and a notice of the
30 benefits in relation to initial coverage limit and annual out-
31 of-pocket threshold for the current year, whenever prescrip-
32 tion drug benefits are provided under this part (except that
33 such notice need not be provided more often than monthly).

34 “(c) ACCESS TO COVERED BENEFITS.—

35 “(1) ASSURING PHARMACY ACCESS.—

36 “(A) IN GENERAL.—The PDP sponsor of the pre-
37 scription drug plan shall secure the participation in its



1 network of a sufficient number of pharmacies that dis-
2 pense (other than by mail order) drugs directly to pa-
3 tients to ensure convenient access (as determined by
4 the Administrator and including adequate emergency
5 access) for enrolled beneficiaries, in accordance with
6 standards established under section 1860D(e) that en-
7 sure such convenient access.

8 “(B) USE OF POINT-OF-SERVICE SYSTEM.—A
9 PDP sponsor shall establish an optional point-of-service
10 method of operation under which—

11 “(i) the plan provides access to any or all
12 pharmacies that are not participating pharmacies
13 in its network; and

14 “(ii) the plan may charge beneficiaries through
15 adjustments in premiums and copayments any ad-
16 ditional costs associated with the point-of-service
17 option.

18 The additional copayments so charged shall not count
19 toward the application of section 1860B(b).

20 “(2) USE OF STANDARDIZED TECHNOLOGY.—

21 “(A) IN GENERAL.—The PDP sponsor of a pre-
22 scription drug plan shall issue (and reissue, as appro-
23 priate) such a card (or other technology) that may be
24 used by an enrolled beneficiary to assure access to ne-
25 gotiated prices under section 1860B(d) for the pur-
26 chase of prescription drugs for which coverage is not
27 otherwise provided under the prescription drug plan.

28 “(B) STANDARDS.—

29 “(i) DEVELOPMENT.—The Administrator shall
30 provide for the development of national standards
31 relating to a standardized format for the card or
32 other technology referred to in subparagraph (A).
33 Such standards shall be compatible with standards
34 established under part C of title XI.

35 “(ii) APPLICATION OF ADVISORY TASK
36 FORCE.—The advisory task force established under
37 subsection (d)(3)(B)(ii) shall provide recommenda-



1 tions to the Administrator under such subsection
2 regarding the standards developed under clause (i).

3 “(3) REQUIREMENTS ON DEVELOPMENT AND APPLICA-
4 TION OF FORMULARIES.—If a PDP sponsor of a prescrip-
5 tion drug plan uses a formulary, the following requirements
6 must be met:

7 “(A) PHARMACY AND THERAPEUTIC (P&T) COM-
8 MITTEE.—The sponsor must establish a pharmacy and
9 therapeutic committee that develops and reviews the
10 formulary. Such committee shall include at least one
11 physician and at least one pharmacist both with exper-
12 tise in the care of elderly or disabled persons and a ma-
13 jority of its members shall consist of individuals who
14 are a physician or a pharmacist (or both).

15 “(B) FORMULARY DEVELOPMENT.—In developing
16 and reviewing the formulary, the committee shall base
17 clinical decisions on the strength of scientific evidence
18 and standards of practice, including assessing peer-re-
19 viewed medical literature, such as randomized clinical
20 trials, pharmacoeconomic studies, outcomes research
21 data, and such other information as the committee de-
22 termines to be appropriate.

23 “(C) INCLUSION OF DRUGS IN ALL THERAPEUTIC
24 CATEGORIES.—The formulary must include drugs with-
25 in each therapeutic category and class of covered out-
26 patient drugs (although not necessarily for all drugs
27 within such categories and classes).

28 “(D) PROVIDER EDUCATION.—The committee
29 shall establish policies and procedures to educate and
30 inform health care providers concerning the formulary.

31 “(E) NOTICE BEFORE REMOVING DRUGS FROM
32 FORMULARY.—Any removal of a drug from a formulary
33 shall take effect only after appropriate notice is made
34 available to beneficiaries and physicians.

35 “(F) GRIEVANCES AND APPEALS RELATING TO AP-
36 PLICATION OF FORMULARIES.—For provisions relating

1 to grievances and appeals of coverage, see subsections
2 (e) and (f).

3 “(d) COST AND UTILIZATION MANAGEMENT; QUALITY AS-
4 SURANCE; MEDICATION THERAPY MANAGEMENT PROGRAM.—

5 “(1) IN GENERAL.—The PDP sponsor shall have in
6 place with respect to covered outpatient drugs—

7 “(A) an effective cost and drug utilization man-
8 agement program, including medically appropriate in-
9 centives to use generic drugs and therapeutic inter-
10 change, when appropriate;

11 “(B) quality assurance measures and systems to
12 reduce medical errors and adverse drug interactions,
13 including a medication therapy management program
14 described in paragraph (2) and for years beginning
15 with 2006, an electronic prescription program described
16 in paragraph (3); and

17 “(C) a program to control fraud, abuse, and
18 waste.

19 Nothing in this section shall be construed as impairing a
20 PDP sponsor from applying cost management tools (includ-
21 ing differential payments) under all methods of operation.

22 “(2) MEDICATION THERAPY MANAGEMENT PRO-
23 GRAM.—

24 “(A) IN GENERAL.—A medication therapy man-
25 agement program described in this paragraph is a pro-
26 gram of drug therapy management and medication ad-
27 ministration that is designed to assure, with respect to
28 beneficiaries with chronic diseases (such as diabetes,
29 asthma, hypertension, and congestive heart failure) or
30 multiple prescriptions, that covered outpatient drugs
31 under the prescription drug plan are appropriately used
32 to achieve therapeutic goals and reduce the risk of ad-
33 verse events, including adverse drug interactions.

34 “(B) ELEMENTS.—Such program may include—

35 “(i) enhanced beneficiary understanding of
36 such appropriate use through beneficiary education,
37 counseling, and other appropriate means;



1 “(ii) increased beneficiary adherence with pre-
2 scription medication regimens through medication
3 refill reminders, special packaging, and other ap-
4 propriate means; and

5 “(iii) detection of patterns of overuse and
6 underuse of prescription drugs.

7 “(C) DEVELOPMENT OF PROGRAM IN COOPERA-
8 TION WITH LICENSED PHARMACISTS.—The program
9 shall be developed in cooperation with licensed phar-
10 macists and physicians.

11 “(D) CONSIDERATIONS IN PHARMACY FEES.—The
12 PDP sponsor of a prescription drug program shall take
13 into account, in establishing fees for pharmacists and
14 others providing services under the medication therapy
15 management program, the resources and time used in
16 implementing the program.

17 “(3) ELECTRONIC PRESCRIPTION PROGRAM.—

18 “(A) IN GENERAL.—An electronic prescription
19 drug program described in this paragraph is a program
20 that includes at least the following components, con-
21 sistent with national standards established under sub-
22 paragraph (B):

23 “(i) ELECTRONIC TRANSMITTAL OF PRESCRIP-
24 TIONS.—Prescriptions are only received electroni-
25 cally, except in emergency cases and other excep-
26 tional circumstances recognized by the Adminis-
27 trator.

28 “(ii) PROVISION OF INFORMATION TO PRE-
29 SCRIBING HEALTH CARE PROFESSIONAL.—The pro-
30 gram provides, upon transmittal of a prescription
31 by a prescribing health care professional, for trans-
32 mittal by the pharmacist to the professional of in-
33 formation that includes—

34 “(I) information (to the extent available
35 and feasible) on the drugs being prescribed for
36 that patient and other information relating to
37 the medical history or condition of the patient



1 that may be relevant to the appropriate pre-
2 scription for that patient;

3 "(II) cost-effective alternatives (if any) for
4 the use of the drug prescribed; and

5 "(III) information on the drugs included
6 in the applicable formulary.

7 To the extent feasible, such program shall permit
8 the prescribing health care professional to provide
9 (and be provided) related information on an inter-
10 active, real-time basis.

11 "(B) STANDARDS.—

12 "(i) DEVELOPMENT.—The Administrator shall
13 provide for the development of national standards
14 relating to the electronic prescription drug program
15 described in subparagraph (A). Such standards
16 shall be compatible with standards established
17 under part C of title XI.

18 "(ii) ADVISORY TASK FORCE.—In developing
19 such standards and the standards described in sub-
20 section (c)(2)(B)(i) the Administrator shall estab-
21 lish a task force that includes representatives of
22 physicians, hospitals, pharmacists, and technology
23 experts and representatives of the Departments of
24 Veterans Affairs and Defense and other appro-
25 priate Federal agencies to provide recommenda-
26 tions to the Administrator on such standards, in-
27 cluding recommendations relating to the following:

28 "(I) The range of available computerized
29 prescribing software and hardware and their
30 costs to develop and implement.

31 "(II) The extent to which such systems re-
32 duce medication errors and can be readily im-
33 plemented by physicians and hospitals.

34 "(III) Efforts to develop a common soft-
35 ware platform for computerized prescribing

36 "(IV) The cost of implementing such sys-
37 tems in the range of hospital and physician of-



1 fice settings, including hardware, software, and
2 training costs.

3 “(V) Implementation issues as they relate
4 to part C of title XI, and current Federal and
5 State prescribing laws and regulations and
6 their impact on implementation of computer-
7 ized prescribing.

8 “(iii) DEADLINES.—

9 “(I) The Administrator shall constitute
10 the task force under clause (ii) by not later
11 than April 1, 2003.

12 “(II) Such task force shall submit rec-
13 ommendations to Administrator by not later
14 than January 1, 2004.

15 “(III) The Administrator shall develop and
16 promulgate the national standards referred to
17 in clause (ii) by not later than July 1, 2004.

18 “(C) REFERENCE TO AVAILABILITY OF GRANT
19 FUNDS.—Grant funds are authorized under section
20 3990 of the Public Health Service Act to provide as-
21 sistance to health care providers in implementing elec-
22 tronic prescription drug programs.

23 “(4) TREATMENT OF ACCREDITATION.—Section
24 1852(e)(4) (relating to treatment of accreditation) shall
25 apply to prescription drug plans under this part with re-
26 spect to the following requirements, in the same manner as
27 they apply to Medicare+Choice plans under part C with re-
28 spect to the requirements described in a clause of section
29 1852(e)(4)(B).

30 “(A) Paragraph (1) (including quality assurance).
31 including medication therapy management program
32 under paragraph (2).

33 “(B) Subsection (c)(1) (relating to access to cov-
34 ered benefits).

35 “(C) Subsection (g) (relating to confidentiality and
36 accuracy of enrollee records).



1 “(5) PUBLIC DISCLOSURE OF PHARMACEUTICAL
2 PRICES FOR EQUIVALENT DRUGS.—Each PDP sponsor
3 shall provide that each pharmacy or other dispenser that
4 arranges for the dispensing of a covered outpatient drug
5 shall inform the beneficiary at the time of purchase of the
6 drug of any differential between the price of the prescribed
7 drug to the enrollee and the price of the lowest cost generic
8 drug covered under the plan that is therapeutically equiva-
9 lent and bioequivalent.

10 “(e) GRIEVANCE MECHANISM, COVERAGE DETERMINA-
11 TIONS, AND RECONSIDERATIONS.—

12 “(1) IN GENERAL.—Each PDP sponsor shall provide
13 meaningful procedures for hearing and resolving grievances
14 between the organization (including any entity or individual
15 through which the sponsor provides covered benefits) and
16 enrollees with prescription drug plans of the sponsor under
17 this part in accordance with section 1852(f).

18 “(2) APPLICATION OF COVERAGE DETERMINATION
19 AND RECONSIDERATION PROVISIONS.—A PDP sponsor
20 shall meet the requirements of paragraphs (1) through (3)
21 of section 1852(g) with respect to covered benefits under
22 the prescription drug plan it offers under this part in the
23 same manner as such requirements apply to a
24 Medicare+Choice organization with respect to benefits it
25 offers under a Medicare+Choice plan under part C

26 “(3) REQUEST FOR REVIEW OF TIERED FORMULARY
27 DETERMINATIONS.—In the case of a prescription drug plan
28 offered by a PDP sponsor that provides for tiered cost-
29 sharing for drugs included within a formulary and provides
30 lower cost-sharing for preferred drugs included within the
31 formulary, an individual who is enrolled in the plan may re-
32 quest coverage of a nonpreferred drug under the terms ap-
33 plicable for preferred drugs if the prescribing physician de-
34 termines that the preferred drug for treatment of the same
35 condition is not as effective for the individual or has ad-
36 verse effects for the individual.

37 “(f) APPEALS.—



1 “(1) IN GENERAL.—Subject to paragraph (2), a PDP
2 sponsor shall meet the requirements of paragraphs (4) and
3 (5) of section 1852(g) with respect to drugs not included
4 on any formulary in the same manner as such requirements
5 apply to a Medicare+Choice organization with respect to
6 benefits it offers under a Medicare+Choice plan under part
7 C.

8 “(2) FORMULARY DETERMINATIONS.—An individual
9 who is enrolled in a prescription drug plan offered by a
10 PDP sponsor may appeal to obtain coverage for a covered
11 outpatient drug that is not on a formulary of the sponsor
12 if the prescribing physician determines that the formulary
13 drug for treatment of the same condition is not as effective
14 for the individual or has adverse effects for the individual.

15 “(g) CONFIDENTIALITY AND ACCURACY OF ENROLLEE
16 RECORDS.—A PDP sponsor shall meet the requirements of sec-
17 tion 1852(h) with respect to enrollees under this part in the
18 same manner as such requirements apply to a
19 Medicare+Choice organization with respect to enrollees under
20 part C.

21 **“SEC. 1860D. REQUIREMENTS FOR PRESCRIPTION DRUG**
22 **PLAN (PDP) SPONSORS; CONTRACTS; ESTAB-**
23 **LISHMENT OF STANDARDS.**

24 “(a) GENERAL REQUIREMENTS.—Each PDP sponsor of a
25 prescription drug plan shall meet the following requirements:

26 “(1) LICENSURE.—Subject to subsection (c), the sponsor
27 is organized and licensed under State law as a risk-
28 bearing entity eligible to offer health insurance or health
29 benefits coverage in each State in which it offers a pre-
30 scription drug plan.

31 “(2) ASSUMPTION OF FINANCIAL RISK.—

32 “(A) IN GENERAL.—Subject to subparagraph (B)
33 and section 1860E(d)(2), the entity assumes full finan-
34 cial risk on a prospective basis for qualified prescrip-
35 tion drug coverage that it offers under a prescription
36 drug plan and that is not covered under section
37 1860H.



1 “(B) REINSURANCE PERMITTED.—The entity may
2 obtain insurance or make other arrangements for the
3 cost of coverage provided to any enrolled member under
4 this part.

5 “(3) SOLVENCY FOR UNLICENSED SPONSORS.—In the
6 case of a sponsor that is not described in paragraph (1),
7 the sponsor shall meet solvency standards established by
8 the Administrator under subsection (d).

9 “(b) CONTRACT REQUIREMENTS.—

10 “(1) IN GENERAL.—The Administrator shall not per-
11 mit the election under section 1860A of a prescription drug
12 plan offered by a PDP sponsor under this part, and the
13 sponsor shall not be eligible for payments under section
14 1860G or 1860H, unless the Administrator has entered
15 into a contract under this subsection with the sponsor with
16 respect to the offering of such plan. Such a contract with
17 a sponsor may cover more than one prescription drug plan.
18 Such contract shall provide that the sponsor agrees to com-
19 ply with the applicable requirements and standards of this
20 part and the terms and conditions of payment as provided
21 for in this part.

22 “(2) NEGOTIATION REGARDING TERMS AND CONDI-
23 TIONS.—The Administrator shall have the same authority
24 to negotiate the terms and conditions of prescription drug
25 plans under this part as the Director of the Office of Per-
26 sonnel Management has with respect to health benefits
27 plans under chapter 89 of title 5, United States Code. In
28 negotiating the terms and conditions regarding premiums
29 for which information is submitted under section
30 1860F(a)(2), the Administrator shall take into account the
31 subsidy payments under section 1860H and the adjusted
32 community rate (as defined in section 1854(f)(3)) for the
33 benefits covered.

34 “(3) INCORPORATION OF CERTAIN MEDICARE+CHOICE
35 CONTRACT REQUIREMENTS.—The following provisions of
36 section 1857 shall apply, subject to subsection (c)(5), to



1 contracts under this section in the same manner as they
2 apply to contracts under section 1857(a):

3 "(A) MINIMUM ENROLLMENT.—Paragraphs (1)
4 and (3) of section 1857(b).

5 "(B) CONTRACT PERIOD AND EFFECTIVENESS.—
6 Paragraphs (1) through (3) and (5) of section 1857(c).

7 "(C) PROTECTIONS AGAINST FRAUD AND BENE-
8 FICIARY PROTECTIONS.—Section 1857(d).

9 "(D) ADDITIONAL CONTRACT TERMS.—Section
10 1857(e); except that in applying section 1857(e) (2)
11 under this part—

12 "(i) such section shall be applied separately to
13 costs relating to this part (from costs under part
14 C);

15 "(ii) in no case shall the amount of the fee es-
16 tablished under this subparagraph for a plan ex-
17 ceed 20 percent of the maximum amount of the fee
18 that may be established under subparagraph (B) of
19 such section; and

20 "(iii) no fees shall be applied under this sub-
21 paragraph with respect to Medicare+Choice plans.

22 "(E) INTERMEDIATE SANCTIONS.—Section
23 1857(g).

24 "(F) PROCEDURES FOR TERMINATION.—Section
25 1857(h).

26 "(4) RULES OF APPLICATION FOR INTERMEDIATE
27 SANCTIONS.—In applying paragraph (3)(E)—

28 "(A) the reference in section 1857(g)(1)(B) to sec-
29 tion 1854 is deemed a reference to this part; and

30 "(B) the reference in section 1857(g)(1)(F) to sec-
31 tion 1852(k)(2)(A)(ii) shall not be applied.

32 "(c) WAIVER OF CERTAIN REQUIREMENTS TO EXPAND
33 CHOICE.—

34 "(1) IN GENERAL.—In the case of an entity that seeks
35 to offer a prescription drug plan in a State, the Adminis-
36 trator shall waive the requirement of subsection (a)(1) that
37 the entity be licensed in that State if the Administrator de-



1 termines, based on the application and other evidence pre-
2 sented to the Administrator, that any of the grounds for
3 approval of the application described in paragraph (2) has
4 been met.

5 “(2) GROUNDS FOR APPROVAL.—The grounds for ap-
6 proval under this paragraph are the grounds for approval
7 described in subparagraph (B), (C), and (D) of section
8 1855(a)(2), and also include the application by a State of
9 any grounds other than those required under Federal law.

10 “(3) APPLICATION OF WAIVER PROCEDURES.—With
11 respect to an application for a waiver (or a waiver granted)
12 under this subsection, the provisions of subparagraphs (E),
13 (F), and (G) of section 1855(a)(2) shall apply.

14 “(4) LICENSURE DOES NOT SUBSTITUTE FOR OR CON-
15 STITUTE CERTIFICATION.—The fact that an entity is li-
16 censed in accordance with subsection (a)(1) does not deem
17 the entity to meet other requirements imposed under this
18 part for a PDP sponsor.

19 “(5) REFERENCES TO CERTAIN PROVISIONS.—For
20 purposes of this subsection, in applying provisions of sec-
21 tion 1855(a)(2) under this subsection to prescription drug
22 plans and PDP sponsors—

23 “(A) any reference to a waiver application under
24 section 1855 shall be treated as a reference to a waiver
25 application under paragraph (1); and

26 “(B) any reference to solvency standards shall be
27 treated as a reference to solvency standards established
28 under subsection (d).

29 “(d) SOLVENCY STANDARDS FOR NON-LICENSED SPON-
30 SORS.—

31 “(1) ESTABLISHMENT.—The Administrator shall es-
32 tablish, by not later than October 1, 2003, financial sol-
33 vency and capital adequacy standards that an entity that
34 does not meet the requirements of subsection (a)(1) must
35 meet to qualify as a PDP sponsor under this part.

36 “(2) COMPLIANCE WITH STANDARDS.—Each PDP
37 sponsor that is not licensed by a State under subsection



1 (a)(1) and for which a waiver application has been ap-
2 proved under subsection (c) shall meet solvency and capital
3 adequacy standards established under paragraph (1). The
4 Administrator shall establish certification procedures for
5 such PDP sponsors with respect to such solvency standards
6 in the manner described in section 1855(c)(2).

7 "(e) OTHER STANDARDS.—The Administrator shall estab-
8 lish by regulation other standards (not described in subsection
9 (d)) for PDP sponsors and plans consistent with, and to carry
10 out, this part. The Administrator shall publish such regulations
11 by October 1, 2003.

12 "(f) RELATION TO STATE LAWS.—

13 "(1) IN GENERAL.—The standards established under
14 this part shall supersede any State law or regulation (other
15 than State licensing laws or State laws relating to plan sol-
16 vency, except as provided in subsection (d)) with respect to
17 prescription drug plans which are offered by PDP sponsors
18 under this part.

19 "(2) PROHIBITION OF STATE IMPOSITION OF PREMIUM
20 TAXES.—No State may impose a premium tax or similar
21 tax with respect to premiums paid to PDP sponsors for
22 prescription drug plans under this part, or with respect to
23 any payments made to such a sponsor by the Administrator
24 under this part.

25 **"SEC. 1860E. PROCESS FOR BENEFICIARIES TO SELECT**
26 **QUALIFIED PRESCRIPTION DRUG COV-**
27 **ERAGE.**

28 "(a) IN GENERAL.—The Administrator shall establish a
29 process for the selection of the prescription drug plan or
30 Medicare+Choice plan which offer qualified prescription drug
31 coverage through which eligible individuals elect qualified pre-
32 scription drug coverage under this part.

33 "(b) ELEMENTS.—Such process shall include the fol-
34 lowing:

35 "(1) Annual, coordinated election periods, in which
36 such individuals can change the qualifying plans through



1 which they obtain coverage, in accordance with section
2 1860A(b)(2).

3 “(2) Active dissemination of information to promote
4 an informed selection among qualifying plans based upon
5 price, quality, and other features, in the manner described
6 in (and in coordination with) section 1851(d), including the
7 provision of annual comparative information, maintenance
8 of a toll-free hotline, and the use of non-Federal entities.

9 “(3) Coordination of elections through filing with a
10 Medicare+Choice organization or a PDP sponsor, in the
11 manner described in (and in coordination with) section
12 1851(c)(2).

13 “(c) MEDICARE+CHOICE ENROLLEE IN PLAN OFFERING
14 PRESCRIPTION DRUG COVERAGE MAY ONLY OBTAIN BENE-
15 FITS THROUGH THE PLAN.—An individual who is enrolled
16 under a Medicare+Choice plan that offers qualified prescrip-
17 tion drug coverage may only elect to receive qualified prescrip-
18 tion drug coverage under this part through such plan.

19 “(d) ASSURING ACCESS TO A CHOICE OF QUALIFIED PRE-
20SCRIPTION DRUG COVERAGE.—

21 “(1) CHOICE OF AT LEAST TWO PLANS IN EACH
22 AREA.—

23 “(A) IN GENERAL.—The Administrator shall as-
24 sure that each individual who is entitled to benefits
25 under part A or enrolled under part B and who is re-
26 siding in an area in the United States has available,
27 consistent with subparagraph (B), a choice of enroli-
28 ment in at least two qualifying plans (as defined in
29 paragraph (5)) in the area in which the individual re-
30 sides, at least one of which is a prescription drug plan.

31 “(B) REQUIREMENT FOR DIFFERENT PLAN SPON-
32 SORS.—The requirement in subparagraph (A) is not
33 satisfied with respect to an area if only one PDP spon-
34 sor or Medicare+Choice organization offers all the
35 qualifying plans in the area.

36 “(2) GUARANTEEING ACCESS TO COVERAGE.—In order
37 to assure access under paragraph (1) and consistent with



paragraph (3), the Administrator may provide financial incentives (including partial underwriting of risk) for a PDP sponsor to expand the service area under an existing prescription drug plan to adjoining or additional areas or to establish such a plan (including offering such a plan on a regional or nationwide basis), but only so long as (and to the extent) necessary to assure the access guaranteed under paragraph (1).

"(3) LIMITATION ON AUTHORITY.—In exercising authority under this subsection, the Administrator—

"(A) shall not provide for the full underwriting of financial risk for any PDP sponsor;

"(B) shall not provide for any underwriting of financial risk for a public PDP sponsor with respect to the offering of a nationwide prescription drug plan; and

"(C) shall seek to maximize the assumption of financial risk by PDP sponsors or Medicare+Choice organizations.

"(4) REPORTS.—The Administrator shall, in each annual report to Congress under section 1808(f), include information on the exercise of authority under this subsection. The Administrator also shall include such recommendations as may be appropriate to minimize the exercise of such authority, including minimizing the assumption of financial risk.

"(5) QUALIFYING PLAN DEFINED.—For purposes of this subsection, the term 'qualifying plan' means a prescription drug plan or a Medicare+Choice plan that includes qualified prescription drug coverage.

"SEC. 1860F. SUBMISSION OF BIDS.

"(a) SUBMISSION OF BIDS AND RELATED INFORMATION.—

"(1) IN GENERAL.—Each PDP sponsor shall submit to the Administrator information of the type described in paragraph (2) in the same manner as information is submitted by a Medicare+Choice organization under section 1854(a)(1).

1 “(2) TYPE OF INFORMATION.—The information de-
2 scribed in this paragraph is the following:

3 “(A) Information on the qualified prescription
4 drug coverage to be provided.

5 “(B) Information on the actuarial value of the cov-
6 erage.

7 “(C) Information on the bid for the coverage, in-
8 cluding an actuarial certification of—

9 “(i) the actuarial basis for such bid;

10 “(ii) the portion of such bid attributable to
11 benefits in excess of standard coverage; and

12 “(iii) the reduction in such bid resulting from
13 the subsidy payments provided under section
14 1860H.

15 “(D) Such other information as the Administrator
16 may require to carry out this part.

17 “(3) REVIEW.—The Administrator shall review the in-
18 formation filed under paragraph (2) for the purpose of con-
19 ducting negotiations under section 1860D(b)(2).

20 “(b) UNIFORM BID.—

21 “(1) IN GENERAL.—The bid for a prescription drug
22 plan under this section may not vary among individuals en-
23 rolled in the plan in the same service area.

24 “(2) CONSTRUCTION.—Nothing in paragraph (1) shall
25 be construed as preventing the imposition of a late enroll-
26 ment penalty under section 1860A(c)(2)(B).

27 “(c) COLLECTION.—

28 “(1) USE OF ELECTRONIC FUNDS TRANSFER MECHA-
29 NISM OR, AT BENEFICIARY'S OPTION, WITHHOLDING FROM
30 SOCIAL SECURITY PAYMENT.—In accordance with regula-
31 tions, a PDP sponsor may encourage that enrollees under
32 a plan make payment of the premium established by the
33 plan under this part through an electronic funds transfer
34 mechanism, such as automatic charges of an account at a
35 financial institution or a credit or debit card account, or,
36 at the option of an enrollee, through withholding from ben-
37 efit payments in the manner provided under section 1840



1 with respect to monthly premiums under section 1839. All
2 such amounts shall be credited to the Medicare Prescrip-
3 tion Drug Trust Fund.

4 “(2) OFFSETTING.—Reductions in premiums for cov-
5 erage under parts A and B as a result of a selection of a
6 Medicare+Choice plan may be used to reduce the premium
7 otherwise imposed under paragraph (1).

8 “(3) PAYMENT OF PLANS.—PDP plans shall receive
9 payment based on bid amounts in the same manner as
10 Medicare+Choice organizations receive payment based on
11 bid amounts under section 1853(a)(1)(A)(ii) except that
12 such payment shall be made from the Medicare Prescrip-
13 tion Drug Trust Fund.

14 “(d) ACCEPTANCE OF BENCHMARK AMOUNT AS FULL
15 PREMIUM FOR SUBSIDIZED LOW-INCOME INDIVIDUALS IF NO
16 STANDARD (OR EQUIVALENT) COVERAGE IN AN AREA.—

17 “(1) IN GENERAL.—If there is no standard prescrip-
18 tion drug coverage (as defined in paragraph (2)) offered in
19 an area, in the case of an individual who is eligible for a
20 premium subsidy under section 1860G and resides in the
21 area, the PDP sponsor of any prescription drug plan of-
22 fered in the area (and any Medicare+Choice organization
23 that offers qualified prescription drug coverage in the area)
24 shall accept the benchmark bid amount (under section
25 1860G(b)(2)) as payment in full for the premium charge
26 for qualified prescription drug coverage.

27 “(2) STANDARD PRESCRIPTION DRUG COVERAGE DE-
28 FINED.—For purposes of this subsection, the term ‘stand-
29 ard prescription drug coverage’ means qualified prescrip-
30 tion drug coverage that is standard coverage or that has
31 an actuarial value equivalent to the actuarial value for
32 standard coverage.

33 **“SEC. 1860G. PREMIUM AND COST-SHARING SUBSIDIES**
34 **FOR LOW-INCOME INDIVIDUALS.**

35 “(a) INCOME-RELATED SUBSIDIES FOR INDIVIDUALS
36 WITH INCOME BELOW 150 PERCENT OF FEDERAL POVERTY
37 LEVEL.—



1 “(1) FULL PREMIUM SUBSIDY AND REDUCTION OF
2 COST-SHARING FOR INDIVIDUALS WITH INCOME BELOW 150
3 PERCENT OF FEDERAL POVERTY LEVEL.—In the case of a
4 subsidy eligible individual (as defined in paragraph (4))
5 who is determined to have income that does not exceed 150
6 percent of the Federal poverty level, the individual is enti-
7 tled under this section—

8 “(A) to an income-related premium subsidy equal
9 to 100 percent of the amount described in subsection
10 (b)(1); and

11 “(B) subject to subsection (c), to the substitution
12 for the beneficiary cost-sharing described in paragraphs
13 (1) and (2) of section 1860B(b) (up to the initial cov-
14 erage limit specified in paragraph (3) of such section)
15 of amounts that do not exceed \$2 for a multiple source
16 or generic drug (as described in section 1927(k)(7)(A))
17 and \$5 for a non-preferred drug.

18 “(2) SLIDING SCALE PREMIUM SUBSIDY AND REDUC-
19 TION OF COST-SHARING FOR INDIVIDUALS WITH INCOME
20 ABOVE 150, BUT BELOW 175 PERCENT, OF FEDERAL POV-
21 ERTY LEVEL.—In the case of a subsidy eligible individual
22 who is determined to have income that exceeds 150 per-
23 cent, but does not exceed 175 percent, of the Federal pov-
24 erty level, the individual is entitled under this section to—

25 “(A) an income-related premium subsidy deter-
26 mined on a linear sliding scale ranging from 100 per-
27 cent of the amount described in subsection (b)(1) for
28 individuals with incomes at 150 percent of such level
29 to 0 percent of such amount for individuals with in-
30 comes at 175 percent of such level; and

31 “(B) subject to subsection (c), to the substitution
32 for the beneficiary cost-sharing described in paragraphs
33 (1) and (2) of section 1860B(b) (up to the initial cov-
34 erage limit specified in paragraph (3) of such section)
35 of amounts that do not exceed \$2 for a multiple source
36 or generic drug (as described in section 1927(k)(7)(A))
37 and \$5 for a non-preferred drug.

1 “(3) CONSTRUCTION.—Nothing in this section shall be
2 construed as preventing a PDP sponsor from reducing to
3 0 the cost-sharing otherwise applicable to generic drugs.

4 “(4) DETERMINATION OF ELIGIBILITY.—

5 “(A) SUBSIDY ELIGIBLE INDIVIDUAL DEFINED.—
6 For purposes of this section, subject to subparagraph
7 (D), the term ‘subsidy eligible individual’ means an in-
8 dividual who—

9 “(i) is eligible to elect, and has elected, to ob-
10 tain qualified prescription drug coverage under this
11 part;

12 “(ii) has income below 175 percent of the Fed-
13 eral poverty line; and

14 “(iii) meets the resources requirement de-
15 scribed in section 1905(p)(1)(C).

16 “(B) DETERMINATIONS.—The determination of
17 whether an individual residing in a State is a subsidy
18 eligible individual and the amount of such individual’s
19 income shall be determined under the State medicaid
20 plan for the State under section 1935(a). In the case
21 of a State that does not operate such a medicaid plan
22 (either under title XIX or under a statewide waiver
23 granted under section 1115), such determination shall
24 be made under arrangements made by the Adminis-
25 trator.

26 “(C) INCOME DETERMINATIONS.—For purposes of
27 applying this section—

28 “(i) income shall be determined in the manner
29 described in section 1905(p)(1)(B); and

30 “(ii) the term ‘Federal poverty line’ means the
31 official poverty line (as defined by the Office of
32 Management and Budget, and revised annually in
33 accordance with section 673(2) of the Omnibus
34 Budget Reconciliation Act of 1981) applicable to a
35 family of the size involved.

36 “(D) TREATMENT OF TERRITORIAL RESIDENTS.—
37 In the case of an individual who is not a resident of



1 the 50 States or the District of Columbia, the indi-
2 vidual is not eligible to be a subsidy eligible individual
3 but may be eligible for financial assistance with pre-
4 scription drug expenses under section 1935(e).

5 "(E) TREATMENT OF CONFORMING MEDIGAP
6 POLICIES.—For purposes of this section, the term
7 'qualified prescription drug coverage' includes a medi-
8 care supplemental policy described in section
9 1860H(b)(4).

10 "(5) INDEXING DOLLAR AMOUNTS.—

11 "(A) FOR 2006.—The dollar amounts applied
12 under paragraphs (1)(B) and (2)(B) for 2006 shall be
13 the dollar amounts specified in such paragraph in-
14 creased by the annual percentage increase described in
15 section 1860B(b)(5) for 2006.

16 "(B) FOR SUBSEQUENT YEARS.—The dollar
17 amounts applied under paragraphs (1)(B) and (2)(B)
18 for a year after 2006 shall be the amounts (under this
19 paragraph) applied under paragraph (1)(B) or (2)(B)
20 for the preceding year increased by the annual percent-
21 age increase described in section 1860B(b)(5) (relating
22 to growth in medicare prescription drug costs per bene-
23 ficiary) for the year involved.

24 "(b) PREMIUM SUBSIDY AMOUNT.—

25 "(1) IN GENERAL.—The premium subsidy amount de-
26 scribed in this subsection for an individual residing in an
27 area is the benchmark bid amount (as defined in paragraph
28 (2)) for qualified prescription drug coverage offered by the
29 prescription drug plan or the Medicare+Choice plan in
30 which the individual is enrolled.

31 "(2) BENCHMARK BID AMOUNT DEFINED.—For pur-
32 poses of this subsection, the term 'benchmark bid amount'
33 means, with respect to qualified prescription drug coverage
34 offered under—

35 "(A) a prescription drug plan that—

36 "(i) provides standard coverage (or alternative
37 prescription drug coverage the actuarial value is

1 equivalent to that of standard coverage), the bid
2 amount for enrollment under the plan under this
3 part (determined without regard to any subsidy
4 under this section or any late enrollment penalty
5 under section 1860A(c)(2)(B)); or

6 “(ii) provides alternative prescription drug
7 coverage the actuarial value of which is greater
8 than that of standard coverage, the bid amount de-
9 scribed in clause (i) multiplied by the ratio of (I)
10 the actuarial value of standard coverage, to (II) the
11 actuarial value of the alternative coverage; or

12 “(B) a Medicare+Choice plan, the portion of the
13 bid amount that is attributable to statutory drug bene-
14 fits (described in section 1853(a)(1)(A)(ii)(II)).

15 “(c) RULES IN APPLYING COST-SHARING SUBSIDIES.—

16 “(1) IN GENERAL.—In applying subsections (a)(1)(B)
17 and (a)(2)(B), nothing in this part shall be construed as
18 preventing a plan or provider from waiving or reducing the
19 amount of cost-sharing otherwise applicable.

20 “(2) LIMITATION ON CHARGES.—In the case of an in-
21 dividual receiving cost-sharing subsidies under subsection
22 (a)(1)(B) or (a)(2)(B), the PDP sponsor may not charge
23 more than \$5 per prescription.

24 “(3) APPLICATION OF INDEXING RULES.—The provi-
25 sions of subsection (a)(4) shall apply to the dollar amount
26 specified in paragraph (2) in the same manner as they
27 apply to the dollar amounts specified in subsections
28 (a)(1)(B) and (a)(2)(B).

29 “(d) ADMINISTRATION OF SUBSIDY PROGRAM.—The Ad-
30 ministrator shall provide a process whereby, in the case of an
31 individual who is determined to be a subsidy eligible individual
32 and who is enrolled in prescription drug plan or is enrolled in
33 a Medicare+Choice plan under which qualified prescription
34 drug coverage is provided—

35 “(1) the Administrator provides for a notification of
36 the PDP sponsor or Medicare+Choice organization in-



1 involved that the individual is eligible for a subsidy and the
2 amount of the subsidy under subsection (a);

3 "(2) the sponsor or organization involved reduces the
4 premiums or cost-sharing otherwise imposed by the amount
5 of the applicable subsidy and submits to the Administrator
6 information on the amount of such reduction; and

7 "(3) the Administrator periodically and on a timely
8 basis reimburses the sponsor or organization for the
9 amount of such reductions.

10 The reimbursement under paragraph (3) with respect to cost-
11 sharing subsidies may be computed on a capitated basis, taking
12 into account the actuarial value of the subsidies and with ap-
13 propriate adjustments to reflect differences in the risks actually
14 involved.

15 "(e) RELATION TO MEDICAID PROGRAM.—

16 "(1) IN GENERAL.—For provisions providing for eligi-
17 bility determinations, and additional financing, under the
18 medicaid program, see section 1935.

19 "(2) MEDICAID PROVIDING WRAP AROUND BENE-
20 FITS.—The coverage provided under this part is primary
21 payor to benefits for prescribed drugs provided under the
22 medicaid program under title XIX.

23 "(3) COORDINATION.—The Administrator shall de-
24 velop and implement a plan for the coordination of pre-
25 scription drug benefits under this part with the benefits
26 provided under the medicaid program under title XIX, with
27 particular attention to insuring coordination of payments
28 and prevention of fraud and abuse. In developing and im-
29 plementing such plan, the Administrator shall involve the
30 Secretary, the States, the data processing industry, phar-
31 macists, and pharmaceutical manufacturers, and other ex-
32 perts.

33 **"SEC. 1860H. SUBSIDIES FOR ALL MEDICARE BENE-**
34 **FICIARIES FOR QUALIFIED PRESCRIPTION**
35 **DRUG COVERAGE.**

36 "(a) SUBSIDY PAYMENT.—In order to reduce premium
37 levels applicable to qualified prescription drug coverage for all

1 medicare beneficiaries, to reduce adverse selection among pre-
2 scription drug plans and Medicare+Choice plans that provide
3 qualified prescription drug coverage, and to promote the par-
4 ticipation of PDP sponsors under this part, the Administrator
5 shall provide in accordance with this section for payment to a
6 qualifying entity (as defined in subsection (b)) of the following
7 subsidies:

8 “(1) DIRECT SUBSIDY.—In the case of an individual
9 enrolled in a prescription drug plan, Medicare+Choice
10 plan, or qualified retiree prescription drug plan, a direct
11 subsidy equal to a percentage (specified by the Adminis-
12 trator consistent with subsection (d)(2)) of an amount
13 equal to the actuarial value of the standard drug coverage
14 provided under the respective plan.

15 “(2) SUBSIDY THROUGH REINSURANCE.—The reinsur-
16 ance payment amount (as defined in subsection (c)) for ex-
17 cess costs incurred in providing qualified prescription drug
18 coverage—

19 “(A) for individuals enrolled with a prescription
20 drug plan under this part:

21 “(B) for individuals enrolled with a
22 Medicare+Choice plan that provides qualified prescrip-
23 tion drug coverage under part C; and

24 “(C) for individuals who are enrolled in a qualified
25 retiree prescription drug plan.

26 This section constitutes budget authority in advance of appro-
27 priations Acts and represents the obligation of the Adminis-
28 trator to provide for the payment of amounts provided under
29 this section.

30 “(b) QUALIFYING ENTITY DEFINED.—For purposes of
31 this section, the term ‘qualifying entity’ means any of the fol-
32 lowing that has entered into an agreement with the Adminis-
33 trator to provide the Administrator with such information as
34 may be required to carry out this section:

35 “(1) A PDP sponsor offering a prescription drug plan
36 under this part.



1 “(2) A Medicare+Choice organization that provides
2 qualified prescription drug coverage under a
3 Medicare+Choice plan under part C.

4 “(3) The sponsor of a qualified retiree prescription
5 drug plan (as defined in subsection (f)).

6 “(c) REINSURANCE PAYMENT AMOUNT.—

7 “(1) IN GENERAL.—Subject to subsection (d)(2) and
8 paragraph (4), the reinsurance payment amount under this
9 subsection for a qualifying covered individual (as defined in
10 subsection (g)(1)) for a coverage year (as defined in sub-
11 section (g)(2)) is equal to the sum of the following:

12 “(A) For the portion of the individual’s gross cov-
13 ered prescription drug costs (as defined in paragraph
14 (3)) for the year that exceeds the initial copayment
15 threshold specified in section 1860B(b)(2)(C), but does
16 not exceed the initial coverage limit specified in section
17 1860B(b)(3), an amount equal to 30 percent of the ai-
18 allowable costs (as defined in paragraph (2)) attributable
19 to such gross covered prescription drug costs.

20 “(B) For the portion of the individual’s gross cov-
21 ered prescription drug costs for the year that exceeds
22 the annual out-of-pocket threshold specified in
23 1860B(b)(4)(B), an amount equal to 80 percent of the
24 allowable costs attributable to such gross covered pre-
25 scription drug costs.

26 “(2) ALLOWABLE COSTS.—For purposes of this sec-
27 tion, the term ‘allowable costs’ means, with respect to gross
28 covered prescription drug costs under a plan described in
29 subsection (b) offered by a qualifying entity, the part of
30 such costs that are actually paid (net of average percentage
31 rebates) under the plan, but in no case more than the part
32 of such costs that would have been paid under the plan if
33 the prescription drug coverage under the plan were stand-
34 ard coverage.

35 “(3) GROSS COVERED PRESCRIPTION DRUG COSTS.—
36 For purposes of this section, the term ‘gross covered pre-
37 scription drug costs’ means, with respect to an enrollee



1 with a qualifying entity under a plan described in sub-
2 section (b) during a coverage year, the costs incurred under
3 the plan (including costs attributable to administrative
4 costs) for covered prescription drugs dispensed during the
5 year, including costs relating to the deductible, whether
6 paid by the enrollee or under the plan, regardless of wheth-
7 er the coverage under the plan exceeds standard coverage
8 and regardless of when the payment for such drugs is
9 made.

10 "(4) INDEXING DOLLAR AMOUNTS.—

11 "(A) AMOUNTS FOR 2005.—The dollar amounts
12 applied under paragraph (1) for 2005 shall be the dol-
13 lar amounts specified in such paragraph.

14 "(B) FOR 2006.—The dollar amounts applied
15 under paragraph (1) for 2006 shall be the dollar
16 amounts specified in such paragraph increased by the
17 annual percentage increase described in section
18 1860B(b)(5) for 2006.

19 "(C) FOR SUBSEQUENT YEARS.—The dollar
20 amounts applied under paragraph (1) for a year after
21 2006 shall be the amounts (under this paragraph) ap-
22 plied under paragraph (1) for the preceding year in-
23 creased by the annual percentage increase described in
24 section 1860B(b)(5) (relating to growth in medicare
25 prescription drug costs per beneficiary) for the year in-
26 volved.

27 "(D) ROUNDING.—Any amount, determined under
28 the preceding provisions of this paragraph for a year,
29 which is not a multiple of \$10 shall be rounded to the
30 nearest multiple of \$10.

31 "(d) ADJUSTMENT OF PAYMENTS.—

32 "(1) ESTIMATION OF PAYMENTS.—The Administrator
33 shall estimate—

34 "(A) the total payments to be made (without re-
35 gard to this subsection) during a year under this sec-
36 tion; and



1 “(B) the total payments to be made by qualifying
2 entities for standard coverage under plans described in
3 subsection (b) during the year.

4 “(2) ADJUSTMENT.—The Administrator shall propor-
5 tionally adjust the payments made under this section for a
6 coverage year in such manner so that—

7 “(A) the total of the payments made for the year
8 under this section is equal to 65 percent of the total
9 payments described in paragraph (1)(B) during the
10 year; and

11 “(B) the ratio of the total of the payments made
12 for direct subsidies under subsection (a)(1) for the year
13 to the total of the payments made for reinsurance sub-
14 sidies for the year under subsection (a)(2) is equal to
15 the ratio of 35 to 30.

16 “(3) RISK ADJUSTMENT.—To the extent the Adminis-
17 trator determines it appropriate to avoid risk selection, the
18 payments made for direct subsidies under subsection (a)(1)
19 are subject to adjustment based upon risk factors specified
20 by the Administrator.

21 “(e) PAYMENT METHODS.—

22 “(1) IN GENERAL.—Payments under this section shall
23 be based on such a method as the Administrator deter-
24 mines. The Administrator may establish a payment method
25 by which interim payments of amounts under this section
26 are made during a year based on the Administrator’s best
27 estimate of amounts that will be payable after obtaining all
28 of the information.

29 “(2) SOURCE OF PAYMENTS.—Payments under this
30 section shall be made from the Medicare Prescription Drug
31 Trust Fund.

32 “(f) QUALIFIED RETIREE PRESCRIPTION DRUG PLAN DE-
33 FINED.—

34 “(1) IN GENERAL.—For purposes of this section, the
35 term ‘qualified retiree prescription drug plan’ means em-
36 ployment-based retiree health coverage (as defined in para-
37 graph (3)(A)) if, with respect to an individual enrolled (or



1 eligible to be enrolled) under this part who is covered under
2 the plan, the following requirements are met:

3 "(A) ASSURANCE.—The sponsor of the plan shall
4 annually attest, and provide such assurances as the Ad-
5 ministrator may require, that the coverage meets or ex-
6 ceeds the requirements for qualified prescription drug
7 coverage.

8 "(B) AUDITS.—The sponsor (and the plan) shall
9 maintain, and afford the Administrator access to, such
10 records as the Administrator may require for purposes
11 of audits and other oversight activities necessary to en-
12 sure the adequacy of prescription drug coverage, and
13 the accuracy of payments made.

14 "(C) PROVISION OF CERTIFICATION OF PRESCRIP-
15 TION DRUG COVERAGE.—The sponsor of the plan shall
16 provide for issuance of certifications of the type de-
17 scribed in section 1860A(c)(2)(D).

18 "(2) LIMITATION ON BENEFIT ELIGIBILITY.—No pay-
19 ment shall be provided under this section with respect to
20 an individual who is enrolled under a qualified retiree pre-
21 scription drug plan unless the individual is—

22 "(A) enrolled under this part;

23 "(B) is covered under the plan; and

24 "(C) is eligible to obtain qualified prescription
25 drug coverage under section 1860A but did not elect
26 such coverage under this part (either through a pre-
27 scription drug plan or through a Medicare+Choice
28 plan).

29 "(3) DEFINITIONS.—As used in this section:

30 "(A) EMPLOYMENT-BASED RETIREE HEALTH COV-
31 ERAGE.—The term 'employment-based retiree health
32 coverage' means health insurance or other coverage of
33 health care costs for individuals enrolled under this
34 part (or for such individuals and their spouses and de-
35 pendents) based on their status as former employees or
36 labor union members.



1 “(B) SPONSOR.—The term ‘sponsor’ means a plan
2 sponsor, as defined in section 3(16)(B) of the Em-
3 ployee Retirement Income Security Act of 1974.

4 “(g) GENERAL DEFINITIONS.—For purposes of this sec-
5 tion:

6 “(1) QUALIFYING COVERED INDIVIDUAL.—The term
7 ‘qualifying covered individual’ means an individual who—

8 “(A) is enrolled with a prescription drug plan
9 under this part:

10 “(B) is enrolled with a Medicare+Choice plan that
11 provides qualified prescription drug coverage under
12 part C; or

13 “(C) is enrolled for benefits under this title and is
14 covered under a qualified retiree prescription drug plan.

15 “(2) COVERAGE YEAR.—The term ‘coverage year’
16 means a calendar year in which covered outpatient drugs
17 are dispensed if a claim for payment is made under the
18 plan for such drugs, regardless of when the claim is paid.

19 **“SEC. 1860I. MEDICARE PRESCRIPTION DRUG TRUST**
20 **FUND.**

21 “(a) IN GENERAL.—There is created on the books of the
22 Treasury of the United States a trust fund to be known as the
23 ‘Medicare Prescription Drug Trust Fund’ (in this section re-
24 ferred to as the ‘Trust Fund’). The Trust Fund shall consist
25 of such gifts and bequests as may be made as provided in sec-
26 tion 201(i)(1), and such amounts as may be deposited in, or
27 appropriated to, such fund as provided in this part. Except as
28 otherwise provided in this section, the provisions of subsections
29 (b) through (i) of section 1841 shall apply to the Trust Fund
30 in the same manner as they apply to the Federal Supple-
31 mentary Medical Insurance Trust Fund under such section.

32 “(b) PAYMENTS FROM TRUST FUND.—

33 “(1) IN GENERAL.—The Managing Trustee shall pay
34 from time to time from the Trust Fund such amounts as
35 the Administrator certifies are necessary to make—

36 “(A) payments under section 1860G (relating to
37 low-income subsidy payments):



1 “(B) payments under section 1860H (relating to
2 subsidy payments); and

3 “(C) payments with respect to administrative ex-
4 penses under this part in accordance with section
5 201(g).

6 “(2) TRANSFERS TO MEDICAID ACCOUNT FOR IN-
7 CREASED ADMINISTRATIVE COSTS.—The Managing Trustee
8 shall transfer from time to time from the Trust Fund to
9 the Grants to States for Medicaid account amounts the Ad-
10 ministrator certifies are attributable to increases in pay-
11 ment resulting from the application of a higher Federal
12 matching percentage under section 1935(b).

13 “(c) DEPOSITS INTO TRUST FUND.—

14 “(1) LOW-INCOME TRANSFER.—There is hereby trans-
15 ferred to the Trust Fund, from amounts appropriated for
16 Grants to States for Medicaid, amounts equivalent to the
17 aggregate amount of the reductions in payments under sec-
18 tion 1903(a)(1) attributable to the application of section
19 1935(c).

20 “(2) APPROPRIATIONS TO COVER GOVERNMENT CON-
21 TRIBUTIONS.—There are authorized to be appropriated
22 from time to time, out of any moneys in the Treasury not
23 otherwise appropriated, to the Trust Fund, an amount
24 equivalent to the amount of payments made from the Trust
25 Fund under subsection (b), reduced by the amount trans-
26 ferred to the Trust Fund under paragraph (1).

27 “(d) RELATION TO SOLVENCY REQUIREMENTS.—Any pro-
28 vision of law that relates to the solvency of the Trust Fund
29 under this part shall take into account the Trust Fund and
30 amounts receivable by, or payable from, the Trust Fund.

31 **“SEC. 1860J. DEFINITIONS; TREATMENT OF REF-**
32 **ERENCES TO PROVISIONS IN PART C.**

33 “(a) DEFINITIONS.—For purposes of this part:

34 “(1) COVERED OUTPATIENT DRUGS.—The term ‘cov-
35 ered outpatient drugs’ is defined in section 1860B(f).

36 “(2) INITIAL COVERAGE LIMIT.—The term ‘initial cov-
37 erage limit’ means such limit as established under section



1 1860B(b)(3), or, in the case of coverage that is not stand-
2 ard coverage, the comparable limit (if any) established
3 under the coverage.

4 "(3) MEDICARE PRESCRIPTION DRUG TRUST FUND.—
5 The term 'Medicare Prescription Drug Trust Fund' means
6 the Trust Fund created under section 1860I(a).

7 "(4) PDP SPONSOR.—The term 'PDP sponsor' means
8 an entity that is certified under this part as meeting the
9 requirements and standards of this part for such a sponsor.

10 "(5) PRESCRIPTION DRUG PLAN.—The term 'prescrip-
11 tion drug plan' means health benefits coverage that—

12 "(A) is offered under a policy, contract, or plan by
13 a PDP sponsor pursuant to, and in accordance with, a
14 contract between the Administrator and the sponsor
15 under section 1860D(b);

16 "(B) provides qualified prescription drug coverage;
17 and

18 "(C) meets the applicable requirements of the sec-
19 tion 1860C for a prescription drug plan.

20 "(6) QUALIFIED PRESCRIPTION DRUG COVERAGE.—
21 The term 'qualified prescription drug coverage' is defined
22 in section 1860B(a).

23 "(7) STANDARD COVERAGE.—The term 'standard cov-
24 erage' is defined in section 1860B(b).

25 "(b) APPLICATION OF MEDICARE+CHOICE PROVISIONS
26 UNDER THIS PART.—For purposes of applying provisions of
27 part C under this part with respect to a prescription drug plan
28 and a PDP sponsor, unless otherwise provided in this part such
29 provisions shall be applied as if—

30 "(1) any reference to a Medicare+Choice plan in-
31 cluded a reference to a prescription drug plan;

32 "(2) any reference to a provider-sponsored organiza-
33 tion included a reference to a PDP sponsor;

34 "(3) any reference to a contract under section 1857
35 included a reference to a contract under section 1860D(b);
36 and



1 “(4) any reference to part C included a reference to
2 this part.”.

3 (b) ADDITIONAL CONFORMING CHANGES.—

4 (1) CONFORMING REFERENCES TO PREVIOUS PART
5 D.—Any reference in law (in effect before the date of the
6 enactment of this Act) to part D of title XVIII of the So-
7 cial Security Act is deemed a reference to part E of such
8 title (as in effect after such date).

9 (2) CONFORMING AMENDMENT PERMITTING WAIVER
10 OF COST-SHARING.—Section 1128B(b)(3) (42 U.S.C.
11 1320a-7b(b)(3)) is amended—

12 (A) by striking “and” at the end of subparagraph
13 (E);

14 (B) by striking the period at the end of subpara-
15 graph (F) and inserting “; and”; and

16 (C) by adding at the end the following new sub-
17 paragraph:

18 “(G) the waiver or reduction of any cost-sharing im-
19 posed under part D of title XVIII.”.

20 (3) SUBMISSION OF LEGISLATIVE PROPOSAL.—Not
21 later than 6 months after the date of the enactment of this
22 Act, the Secretary of Health and Human Services shall
23 submit to the appropriate committees of Congress a legisla-
24 tive proposal providing for such technical and conforming
25 amendments in the law as are required by the provisions
26 of this subtitle.

27 (c) STUDY ON TRANSITIONING PART B PRESCRIPTION
28 DRUG COVERAGE.—Not later than January 1, 2004, the Medi-
29 care Benefits Administrator shall submit a report to Congress
30 that makes recommendations regarding methods for providing
31 benefits under part D of title XVIII of the Social Security Act
32 for outpatient prescription drugs for which benefits are pro-
33 vided under part B of such title.



1 **SEC. 102. OFFERING OF QUALIFIED PRESCRIPTION**
2 **DRUG COVERAGE UNDER THE**
3 **MEDICARE+CHOICE PROGRAM.**

4 (a) IN GENERAL.—Section 1851 (42 U.S.C. 1395w-21) is
5 amended by adding at the end the following new subsection:

6 “(j) AVAILABILITY OF PRESCRIPTION DRUG BENEFITS.—

7 “(1) OFFER OF QUALIFIED PRESCRIPTION DRUG COV-
8 ERAGE.—

9 “(A) IN GENERAL.—A Medicare+Choice organiza-
10 tion may not offer prescription drug coverage (other
11 than that required under parts A and B) to an enrollee
12 under a Medicare+Choice plan unless such drug cov-
13 erage is at least qualified prescription drug coverage
14 and unless the requirements of this subsection with re-
15 spect to such coverage are met.

16 “(B) CONSTRUCTION.—Nothing in this subsection
17 shall be construed as—

18 “(i) requiring a Medicare+Choice plan to in-
19 clude coverage of qualified prescription drug cov-
20 erage; or

21 “(ii) permitting a Medicare+Choice organiza-
22 tion from providing such coverage to an individual
23 who has not elected such coverage under section
24 1860A(b).

25 For purposes of this part, an individual who has not
26 elected qualified prescription drug coverage under sec-
27 tion 1860A(b) shall be treated as being ineligible to en-
28 roll in a Medicare+Choice plan under this part that of-
29 fers such coverage.

30 “(2) COMPLIANCE WITH ADDITIONAL BENEFICIARY
31 PROTECTIONS.—With respect to the offering of qualified
32 prescription drug coverage by a Medicare+Choice organiza-
33 tion under a Medicare+Choice plan, the organization and
34 plan shall meet the requirements of section 1860C, includ-
35 ing requirements relating to information dissemination and
36 grievance and appeals, in the same manner as they apply
37 to a PDP sponsor and a prescription drug plan under part



1 D and shall submit to the Administrator the information
2 described in section 1860F(a)(2). The Administrator shall
3 waive such requirements to the extent the Administrator
4 determines that such requirements duplicate requirements
5 otherwise applicable to the organization or plan under this
6 part.

7 “(3) AVAILABILITY OF PREMIUM AND COST-SHARING
8 SUBSIDIES FOR LOW-INCOME ENROLLEES AND DIRECT AND
9 REINSURANCE SUBSIDY PAYMENTS FOR ORGANIZATIONS.—
10 For provisions—

11 “(A) providing premium and cost-sharing subsidies
12 to low-income individuals receiving qualified prescrip-
13 tion drug coverage through a Medicare+Choice plan,
14 see section 1860G; and

15 “(B) providing a Medicare+Choice organization
16 with direct and insurance subsidy payments for pro-
17 viding qualified prescription drug coverage under this
18 part, see section 1860H.

19 “(4) TRANSITION IN INITIAL ENROLLMENT PERIOD.—
20 Notwithstanding any other provision of this part, the an-
21 nual, coordinated election period under subsection (e)(3)(B)
22 for 2005 shall be the 6-month period beginning with No-
23 vember 2004.

24 “(5) QUALIFIED PRESCRIPTION DRUG COVERAGE:
25 STANDARD COVERAGE.—For purposes of this part, the
26 terms ‘qualified prescription drug coverage’ and ‘standard
27 coverage’ have the meanings given such terms in section
28 1860E.”

29 (b) CONFORMING AMENDMENTS.—Section 1851 (42
30 U.S.C. 1395w-21) is amended—

31 (1) in subsection (a)(1)—

32 (A) by inserting “(other than qualified prescrip-
33 tion drug benefits)” after “benefits”;

34 (B) by striking the period at the end of subpara-
35 graph (B) and inserting a comma; and

36 (C) by adding after and below subparagraph (B)
37 the following:



1 "and may elect qualified prescription drug coverage in ac-
2 cordance with section 1860A."; and

3 (2) in subsection (g)(1), by inserting "and section
4 1860A(c)(2)(B)" after "in this subsection".

5 (c) EFFECTIVE DATE.—The amendments made by this
6 section apply to coverage provided on or after January 1, 2005.

7 **SEC. 103. MEDICAID AMENDMENTS.**

8 (a) DETERMINATIONS OF ELIGIBILITY FOR LOW-INCOME
9 SUBSIDIES.—

10 (1) REQUIREMENT.—Section 1902(a) (42 U.S.C.
11 1396a(a)) is amended—

12 (A) by striking "and" at the end of paragraph
13 (64);

14 (B) by striking the period at the end of paragraph
15 (65) and inserting "; and"; and

16 (C) by inserting after paragraph (65) the following
17 new paragraph:

18 "(66) provide for making eligibility determinations
19 under section 1935(a).".

20 (2) NEW SECTION.—Title XIX is further amended—

21 (A) by redesignating section 1935 as section 1936;
22 and

23 (B) by inserting after section 1934 the following
24 new section:

25 "SPECIAL PROVISIONS RELATING TO MEDICARE PRESCRIPTION
26 DRUG BENEFIT

27 "SEC. 1935. (a) REQUIREMENT FOR MAKING ELIGIBILITY
28 DETERMINATIONS FOR LOW-INCOME SUBSIDIES.—As a condi-
29 tion of its State plan under this title under section 1902(a)(66)
30 and receipt of any Federal financial assistance under section
31 1903(a), a State shall—

32 "(1) make determinations of eligibility for premium
33 and cost-sharing subsidies under (and in accordance with)
34 section 1860G;

35 "(2) inform the Administrator of the Medicare Bene-
36 fits Administration of such determinations in cases in
37 which such eligibility is established; and

1 “(3) otherwise provide such Administrator with such
2 information as may be required to carry out part D of title
3 XVIII (including section 1860G).

4 “(b) PAYMENTS FOR ADDITIONAL ADMINISTRATIVE
5 COSTS.—

6 “(1) IN GENERAL.—The amounts expended by a State
7 in carrying out subsection (a) are, subject to paragraph
8 (2), expenditures reimbursable under the appropriate para-
9 graph of section 1903(a); except that, notwithstanding any
10 other provision of such section, the applicable Federal
11 matching rates with respect to such expenditures under
12 such section shall be increased as follows (but in no case
13 shall the rate as so increased exceed 100 percent):

14 “(A) For expenditures attributable to costs in-
15 curred during 2005, the otherwise applicable Federal
16 matching rate shall be increased by 10 percent of the
17 percentage otherwise payable (but for this subsection)
18 by the State.

19 “(B)(i) For expenditures attributable to costs in-
20 curred during 2006 and each subsequent year through
21 2013, the otherwise applicable Federal matching rate
22 shall be increased by the applicable percent (as defined
23 in clause (ii)) of the percentage otherwise payable (but
24 for this subsection) by the State.

25 “(ii) For purposes of clause (i), the ‘applicable
26 percent’ for—

27 “(I) 2006 is 20 percent; or

28 “(II) a subsequent year is the applicable per-
29 cent under this clause for the previous year in-
30 creased by 10 percentage points.

31 “(C) For expenditures attributable to costs in-
32 curred after 2013, the otherwise applicable Federal
33 matching rate shall be increased to 100 percent.

34 “(2) COORDINATION.—The State shall provide the Ad-
35 ministrator with such information as may be necessary to
36 properly allocate administrative expenditures described in



1 paragraph (1) that may otherwise be made for similar eligi-
2 bility determinations.”

3 (b) PHASED-IN FEDERAL ASSUMPTION OF MEDICAID RE-
4 SPONSIBILITY FOR PREMIUM AND COST-SHARING SUBSIDIES
5 FOR DUALY ELIGIBLE INDIVIDUALS.—

6 (1) IN GENERAL.—Section 1903(a)(1) (42 U.S.C.
7 1396b(a)(1)) is amended by inserting before the semicolon
8 the following: “, reduced by the amount computed under
9 section 1935(c)(1) for the State and the quarter”.

10 (2) AMOUNT DESCRIBED.—Section 1935, as inserted
11 by subsection (a)(2), is amended by adding at the end the
12 following new subsection:

13 “(c) FEDERAL ASSUMPTION OF MEDICAID PRESCRIPTION
14 DRUG COSTS FOR DUALY-ELIGIBLE BENEFICIARIES.—

15 “(1) IN GENERAL.—For purposes of section
16 1903(a)(1), for a State that is one of the 50 States or the
17 District of Columbia for a calendar quarter in a year (be-
18 ginning with 2005) the amount computed under this sub-
19 section is equal to the product of the following:

20 “(A) MEDICARE SUBSIDIES.—The total amount of
21 payments made in the quarter under section 1860G
22 (relating to premium and cost-sharing prescription
23 drug subsidies for low-income medicare beneficiaries)
24 that are attributable to individuals who are residents of
25 the State and are entitled to benefits with respect to
26 prescribed drugs under the State plan under this title
27 (including such a plan operating under a waiver under
28 section 1115).

29 “(B) STATE MATCHING RATE.—A proportion com-
30 puted by subtracting from 100 percent the Federal
31 medical assistance percentage (as defined in section
32 1905(b)) applicable to the State and the quarter.

33 “(C) PHASE-OUT PROPORTION.—The phase-out
34 proportion (as defined in paragraph (2)) for the quar-
35 ter.

1 “(2) PHASE-OUT PROPORTION.—For purposes of para-
2 graph (1)(C), the ‘phase-out proportion’ for a calendar
3 quarter in—

4 “(A) 2005 is 90 percent;

5 “(B) a subsequent year before 2014, is the phase-
6 out proportion for calendar quarters in the previous
7 year decreased by 10 percentage points; or

8 “(C) a year after 2013 is 0 percent.”.

9 (c) MEDICAID PROVIDING WRAP-AROUND BENEFITS.—

10 Section 1935, as so inserted and amended, is further amended
11 by adding at the end the following new subsection:

12 “(d) ADDITIONAL PROVISIONS.—

13 “(1) MEDICAID AS SECONDARY PAYOR.—In the case of
14 an individual who is entitled to qualified prescription drug
15 coverage under a prescription drug plan under part D of
16 title XVIII (or under a Medicare+Choice plan under part
17 C of such title) and medical assistance for prescribed drugs
18 under this title, medical assistance shall continue to be pro-
19 vided under this title for prescribed drugs to the extent
20 payment is not made under the prescription drug plan or
21 the Medicare+Choice plan selected by the individual.

22 “(2) CONDITION.—A State may require, as a condition
23 for the receipt of medical assistance under this title with
24 respect to prescription drug benefits for an individual eligi-
25 ble to obtain qualified prescription drug coverage described
26 in paragraph (1), that the individual elect qualified pre-
27 scription drug coverage under section 1860A.”.

28 (d) TREATMENT OF TERRITORIES.—

29 (1) IN GENERAL.—Section 1935, as so inserted and
30 amended, is further amended—

31 (A) in subsection (a) in the matter preceding para-
32 graph (1), by inserting “subject to subsection (e)” after
33 “section 1903(a)”;

34 (B) in subsection (c)(1), by inserting “subject to
35 subsection (e)” after “1903(a)(1)”; and

36 (C) by adding at the end the following new sub-
37 section:



1 “(e) TREATMENT OF TERRITORIES.—

2 “(1) IN GENERAL.—In the case of a State, other than
3 the 50 States and the District of Columbia—

4 “(A) the previous provisions of this section shall
5 not apply to residents of such State; and

6 “(B) if the State establishes a plan described in
7 paragraph (2) (for providing medical assistance with
8 respect to the provision of prescription drugs to medi-
9 care beneficiaries), the amount otherwise determined
10 under section 1108(f) (as increased under section
11 1108(g)) for the State shall be increased by the
12 amount specified in paragraph (3).

13 “(2) PLAN.—The plan described in this paragraph is
14 a plan that—

15 “(A) provides medical assistance with respect to
16 the provision of covered outpatient drugs (as defined in
17 section 1860B(f)) to low-income medicare beneficiaries;
18 and

19 “(B) assures that additional amounts received by
20 the State that are attributable to the operation of this
21 subsection are used only for such assistance.

22 “(3) INCREASED AMOUNT.—

23 “(A) IN GENERAL.—The amount specified in this
24 paragraph for a State for a year is equal to the product
25 of—

26 “(i) the aggregate amount specified in sub-
27 paragraph (B); and

28 “(ii) the amount specified in section
29 1108(g)(1) for that State, divided by the sum of
30 the amounts specified in such section for all such
31 States.

32 “(B) AGGREGATE AMOUNT.—The aggregate
33 amount specified in this subparagraph for—

34 “(i) 2005, is equal to \$20,000,000; or

35 “(ii) a subsequent year, is equal to the aggre-
36 gate amount specified in this subparagraph for the
37 previous year increased by annual percentage in-



1 crease specified in section 1860B(b)(5) for the year
2 involved.

3 “(4) REPORT.—The Administrator shall submit to
4 Congress a report on the application of this subsection and
5 may include in the report such recommendations as the Ad-
6 ministrator deems appropriate.”.

7 (2) CONFORMING AMENDMENT.—Section 1108(f) (42
8 U.S.C. 1308(f)) is amended by inserting “and section
9 1935(e)(1)(B)” after “Subject to subsection (g)”.

10 **SEC. 104. MEDIGAP TRANSITION.**

11 (a) IN GENERAL.—Section 1882 (42 U.S.C. 1395ss) is
12 amended by adding at the end the following new subsection:

13 “(v) COVERAGE OF PRESCRIPTION DRUGS.—

14 “(1) IN GENERAL.—Notwithstanding any other provi-
15 sion of law, except as provided in paragraph (3) no new
16 medicare supplemental policy that provides coverage of ex-
17 penses for prescription drugs may be issued under this sec-
18 tion on or after January 1, 2005, to an individual unless
19 it replaces a medicare supplemental policy that was issued
20 to that individual and that provided some coverage of ex-
21 penses for prescription drugs.

22 “(2) ISSUANCE OF SUBSTITUTE POLICIES IF OBTAIN
23 PRESCRIPTION DRUG COVERAGE UNDER PART D.—

24 “(A) IN GENERAL.—The issuer of a medicare sup-
25 plemental policy—

26 “(i) may not deny or condition the issuance or
27 effectiveness of a medicare supplemental policy that
28 has a benefit package classified as ‘A’, ‘B’, ‘C’, ‘D’,
29 ‘E’, ‘F’, or ‘G’ (under the standards established
30 under subsection (p)(2)) and that is offered and is
31 available for issuance to new enrollees by such
32 issuer;

33 “(ii) may not discriminate in the pricing of
34 such policy, because of health status, claims experi-
35 ence, receipt of health care, or medical condition,
36 and



1 “(iii) may not impose an exclusion of benefits
2 based on a pre-existing condition under such policy.
3 in the case of an individual described in subparagraph
4 (B) who seeks to enroll under the policy not later than
5 63 days after the date of the termination of enrollment
6 described in such paragraph and who submits evidence
7 of the date of termination or disenrollment along with
8 the application for such medicare supplemental policy.

9 “(B) INDIVIDUAL COVERED.—An individual de-
10 scribed in this subparagraph is an individual who—

11 “(i) enrolls in a prescription drug plan under
12 part D; and

13 “(ii) at the time of such enrollment was en-
14 rolled and terminates enrollment in a medicare sup-
15 plemental policy which has a benefit package classi-
16 fied as ‘H’, ‘I’, or ‘J’ under the standards referred
17 to in subparagraph (A)(i) or terminates enrollment
18 in a policy to which such standards do not apply
19 but which provides benefits for prescription drugs.

20 “(C) ENFORCEMENT.—The provisions of para-
21 graph (4) of subsection (s) shall apply with respect to
22 the requirements of this paragraph in the same manner
23 as they apply to the requirements of such subsection.

24 “(3) NEW STANDARDS.—In applying subsection
25 (p)(1)(E) (including permitting the NAIC to revise its
26 model regulations in response to changes in law) with re-
27 spect to the change in benefits resulting from title I of the
28 Medicare Modernization and Prescription Drug Act of
29 2002, with respect to policies issued to individuals who are
30 enrolled under part D, the changes in standards shall pro-
31 vide for at least two benefit packages (other than the core
32 benefit package) that may provide for coverage of cost-
33 sharing with respect to qualified prescription drug coverage
34 under such part, except that such coverage may not cover
35 the prescription drug deductible under such part. Two ben-
36 efit packages shall be consistent with the following:



1 “(A) FIRST NEW POLICY.—The policy described in
2 this subparagraph has the following benefits, notwith-
3 standing any other provision of this section relating to
4 a core benefit package:

5 “(i) Coverage of 50 percent of the cost-sharing
6 otherwise applicable, except coverage of 100 per-
7 cent of any cost-sharing otherwise applicable for
8 preventive benefits.

9 “(ii) No coverage of the part B deductible.

10 “(iii) Coverage for all hospital coinsurance for
11 long stays (as in the current core benefit package).

12 “(iv) A limitation on annual out-of-pocket ex-
13 penditures to \$4,000 in 2005 (or, in a subsequent
14 year, to such limitation for the previous year in-
15 creased by an appropriate inflation adjustment
16 specified by the Secretary).

17 “(B) SECOND NEW POLICY.—The policy described
18 in this subparagraph has the same benefits as the poi-
19 icy described in subparagraph (A), except as follows:

20 “(i) Substitute ‘75 percent’ for ‘50 percent’ in
21 clause (i) of such subparagraph.

22 “(ii) Substitute ‘\$2,000’ for ‘\$4,000’ in clause
23 (iv) of such subparagraph.

24 “(4) CONSTRUCTION.—Any provision in this section or
25 in a medicare supplemental policy relating to guaranteed
26 renewability of coverage shall be deemed to have been met
27 through the offering of other coverage under this sub-
28 section.”

29 **SEC. 105. MEDICARE PRESCRIPTION DRUG DISCOUNT**
30 **CARD ENDORSEMENT PROGRAM.**

31 Title XVIII is amended by inserting after section 1806 the
32 following new section:

33 “MEDICARE PRESCRIPTION DRUG DISCOUNT CARD
34 ENDORSEMENT PROGRAM.

35 “SEC. 1807. (a) IN GENERAL.—The Secretary (or the
36 Medicare Benefits Administrator pursuant to section
37 1808(c)(3)(C)) shall establish a program:—

1 “(1) to endorse prescription drug discount card pro-
2 grams that meet the requirements of this section; and

3 “(2) to make available to medicare beneficiaries infor-
4 mation regarding such endorsed programs.

5 “(b) REQUIREMENTS FOR ENDORSEMENT.—The Secretary
6 may not endorse a prescription drug discount card program
7 under this section unless the program meets the following re-
8 quirements:

9 “(1) SAVINGS TO MEDICARE BENEFICIARIES.—The
10 program passes on to medicare beneficiaries who enroll in
11 the program discounts on prescription drugs, including dis-
12 counts negotiated with manufacturers.

13 “(2) PROHIBITION ON APPLICATION ONLY TO MAIL
14 ORDER.—The program applies to drugs that are available
15 other than solely through mail order.

16 “(3) BENEFICIARY SERVICES.—The program provides
17 pharmaceutical support services, such as education and
18 counseling, and services to prevent adverse drug inter-
19 actions.

20 “(4) INFORMATION.—The program makes available to
21 medicare beneficiaries through the Internet and otherwise
22 information, including information on enrollment fees,
23 prices charged to beneficiaries, and services offered under
24 the program, that the Secretary identifies as being nec-
25 essary to provide for informed choice by beneficiaries
26 among endorsed programs.

27 “(5) DEMONSTRATED EXPERIENCE.—The entity oper-
28 ating the program has demonstrated experience and exper-
29 tise in operating such a program or a similar program.

30 “(6) QUALITY ASSURANCE.—The entity has in place
31 adequate procedures for assuring quality service under the
32 program.

33 “(7) ADDITIONAL BENEFICIARY PROTECTIONS.—The
34 program meets such additional requirements as the Sec-
35 retary identifies to protect and promote the interest of
36 medicare beneficiaries, including requirements that ensure
37 that beneficiaries are not charged more than the lower of



1 the negotiated retail price or the usual and customary
2 price.

3 "(c) PROGRAM OPERATION.—The Secretary shall operate
4 the program under this section consistent with the following:

5 "(1) PROMOTION OF INFORMED CHOICE.—In order to
6 promote informed choice among endorsed prescription drug
7 discount card programs, the Secretary shall provide for the
8 dissemination of information which compares the costs and
9 benefits of such programs in a manner coordinated with
10 the dissemination of educational information on
11 Medicare+Choice plans under part C.

12 "(2) OVERSIGHT.—The Secretary shall provide appro-
13 priate oversight to ensure compliance of endorsed programs
14 with the requirements of this section, including verification
15 of the discounts and services provided.

16 "(3) USE OF MEDICARE TOLL-FREE NUMBER.—The
17 Secretary shall provide through the 1-800-medicare toll free
18 telephone number for the receipt and response to inquiries
19 and complaints concerning the program and programs en-
20 dored under this section.

21 "(4) DISQUALIFICATION FOR ABUSIVE PRACTICES.—
22 The Secretary shall revoke the endorsement of a program
23 that the Secretary determines no longer meets the require-
24 ments of this section or that has engaged in false or mis-
25 leading marketing practices.

26 "(5) ENROLLMENT PRACTICES.—A medicare bene-
27 ficiary may not be enrolled in more than one endorsed pro-
28 gram at any time.

29 "(d) TRANSITION.—The Secretary shall provide for an ap-
30 propriate transition and discontinuation of the program under
31 this section at the time prescription drug benefits first become
32 available under part D.

33 "(e) AUTHORIZATION OF APPROPRIATIONS.—There are
34 authorized to be appropriated such sums as may be necessary
35 to carry out the program under this section."



